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Estimating the marginal productivity of the English National Health Service 
from 2003/04 to 2012/13
Abstract
Estimates of the marginal productivity of the health sector are required for a wide range of resource 
allocation decisions.  Founding these estimates on robust empirical analysis can inform these 
decisions and improve allocative efficiency.  This paper estimates the annual marginal productivity of 
the English NHS over a ten year period (between 2003/04 and 2012/13).  Data on expenditure and 
mortality by programme budget category are used in conjunction with socio-economic and 
demographic variables from the censuses for 2001 and 2011.  This paper applies an econometric 
strategy that employs an established instrumental variable approach, which is then subjected to a 
number of sensitivity analyses.  The results of the econometric analysis, along with additional data 
on the burden of disease, are used to generate an estimate of the marginal productivity for each of 
the study years.  We find that an additional unit of health benefit has cost between £5,000 and 
£15,000 per quality-adjusted life year between 2003/04 and 2012/13.  Over this period these 
estimates (all in current prices) have increased at a faster rate than NHS price inflation suggesting an 
increase in real terms. These results are discussed in the context of the existing literature, and the 
potential policy implications for decisions about resource allocation are explored.
Keywords: productivity; econometric modelling; programme budgeting; health opportunity costs; 
allocative efficiency 













































































Although useful for resource allocation decisions, reliable estimates of the size of the causal link 
between healthcare expenditure and health outcomes are difficult to obtain.  This is partly because 
of several empirical challenges including the heterogeneity of observational units and that mortality 
might be influenced by expenditure and also influence it (reverse causality).1 For these and other 
reasons, several studies have failed to identify a strong and consistent relationship between 
healthcare expenditure and health outcomes (after controlling for other factors).2
In a bid to overcome these econometric challenges and to provide policy-relevant estimates of 
marginal productivity for national decision making, recent studies have started to employ 
instrumental variable-based (IV) regression approaches using sub-national rather than cross-country 
data.3–8  A sub-national approach has considerable advantages over the use of aggregate country 
level data e.g., it permits the inclusion of a broader range of variables since numerous sources of 
data can be linked and available data are not constrained by the need for international 
comparability. 
Several sub-national studies use English data that reflects local-level information on expenditure, 
outcomes and other factors.3–7  Although these studies use similar datasets, they differ in how the 
effect of expenditure on outcomes is identified using IVs.i   One approach directly estimates the 
elasticity of all-cause mortality with respect to health expenditure.6  Here, the IVs are chosen on the 
basis that the per capita budget assigned to each health authority is the product of the national per 
capita budget and four adjustments reflecting local circumstances, three of which are plausibly 
unrelated to mortality and are therefore suitable as instruments.ii   
The other approach3–5 uses data on expenditure and outcomes in different disease areas 
(programme budget categories, PBCs) reported at a local level (for English primary care trusts, PCTs).  
An expenditure equation is estimated to quantify how the overall budget is allocated across PBCs, 
and an outcome equation is estimated to quantify the elasticity of PBC-specific mortality with 
respect to PBC-specific healthcare expenditure.  The IVs used in this approach, and also employed in 
this paper, reflect factors, such as socio-economic deprivation and the availability of informal care in 
the community, which are believed to influence healthcare expenditure but plausibly only indirectly 
impact on mortality through their impact on expenditure.  This second strategy for finding IVs has 
also been employed in the analysis of Australian data where an elasticity of all-cause mortality with 
respect to health expenditure of -2.2 is reported.7,8
The disease-specific elasticities of mortality with respect to expenditure are interesting results in 
themselves, but they do not fully express the marginal productivity of the NHS in the most useful 
way possible. This is because the NHS is not only concerned with extending life, but with improving 
the quality of life.  Therefore, a measure of marginal productivity should ideally reflect the effect of 
NHS expenditures on extending survival (resulting from reduced mortality) as well as improving 
i A third approach has recently been explored.28  It is essentially a hybrid of the two approaches described in 
the text.  This third approach employs IVs for total expenditure in order to estimate elasticities for PBC-specific 
mortalities instead of all-cause mortality. This approach is a promising avenue for future research as one 
benefit is that it is no longer assumed that mortality in a PBC is unaffected by spending in other PBCs.
ii These four adjustments are the local age index, local additional needs index, local input price index and local 
distance from target Index. The authors argue that all are potentially exogenous with the exception of the local 
additional needs index.












































































health-related quality of life.  Such a measure can be obtained by combining health outcome and 
expenditure elasticities with additional information about disease-specific life expectancy and 
morbidity burden by age and gender of the patient population.5   This study5 reports a cost per life-
year of £25 214 for 2008/9; this reflects an estimate of marginal productivity that captures the effect 
of HS expenditure on extending survival only.  But, by using the effect of expenditure on the 
mortality as a surrogate for the effect on a measure of health burden that also includes morbidity 
burden, the study5 also reports a cost per QALY of £12 936 for 2008/9 and this reflects the likely 
impact of expenditure at the margin on both mortality and morbidity.
This paper builds on and extends a recent study.5  That study reported cost per QALY estimates for 
three years (2006/7, 2007/8 and 2008/9) using PCTs as the unit of analysis and all census-based 
variables reflected 2001 data.  Mortality data ceased to be available for PCTs after 2008/9/10 and 
hence, to facilitate updates, the unit of analysis used here is the ‘upper-tier’ local government 
geography.  Moreover, the 2011 census is used to update the (2001) census-based variables.  This 
paper reports estimates of the marginal productivity of the English NHS, annually, for the ten year 
period between 2003/04 and 2012/13.  It applies the methodology used in previous work5 to new 
data, constructed for a different unit of analysis, and undertakes a range of additional sensitivity 
analyses. 
The plan of the paper is as follows.  The datasets are described in section 2, along with an overview 
of the empirical approach to estimation. In section 3, annual marginal productivity results for the 
ten-year period (both point estimates and key percentiles of the distribution) are expressed in terms 
of the amount of resource used to produce a unit of health benefit (cost per QALY) and the volume 
of health benefits produced using a unit of resource (QALYs per unit of expenditure).  These results 
are discussed in section 4, before a conclusion is presented in section 5.  Additional information 
about the methods, and results from the sensitivity analyses, are presented in the Appendix.
2. Methods
2.1 Data
This paper uses three sources of data to examine the relationship between NHS expenditure and 
mortality.  NHS expenditure (adjusted for unavoidable cost-factors) by geographically defined local 
health authorities, PCTs, is available for 23 programme budget categories (PBCs), annually, for 
2003/4 to 2012/13, and this includes virtually all NHS expenditure on inpatient care, outpatient and 
community care, and pharmaceutical prescriptions.iii  Mortality rates (standardised years of life lost 
rates, SYLLR) are available for ten budget categories at the local authority level averaged over three-
year periods from 2003/04/05 to 2012/13/14.  Finally, UK census data for 2001 and 2011 are used to 
construct a dozen socio-economic variables that were used by Claxton et al (2015).  These variables 
include measures of: the proportion of residents are born outside the European Union; the 
proportion of the working-age population are employed in managerial and professional occupations; 
the proportion of households that are owner occupied; and the proportion of the population that 
provides unpaid care.  Further details about the census-based variables can be found in the appendix 
(see section A2.1).  In the absence of intermediate observations, values for 2003 to 2010 are linearly 
iii Note that this dataset does not include non-NHS expenditures on health. This makes the resulting estimate 
useful mainly for decisions that concern the NHS and would not be directly relevant for decision making in the 
comparably small UK private healthcare sector.












































































interpolated from those observed for 2001 and 2011, and the value for 2012 is assumed to be the 
same as that recorded by the census for 2011.  These socio-economic variables are available as 
potential controls in the second-stage equation and as potential instruments for the first-stage. 
We adopt English local authorities as a consistent geographical unit of analysis across these different 
sources and years of data.  Mortality and census variables are directly available at LA-level.  
However, the remaining variables (including the PBC expenditure data) are only available at PCT-
level and these data are mapped from PCT to LA-level using a tool developed by the UK Department 
of Health.  The sensitivity of the results to the mapping tool was investigated as part of preliminary 
work, using data from 2008/09 where both PCT-level and LA-level are available, and the results were 
largely robust to inaccuracies resulting from the mapping process.9
2.2 Econometric strategy
Our modelling framework derives from an underlying conceptual model that assumes that each PCT 
manager receives a fixed annual budget and allocates it across the 23 programmes of care so as to 
maximise social welfare subject to a health production function.  The optimal level of spending for a 
given PBC is a function of the total PCT budget, the need for healthcare spending in that disease 
area, environmental factors that affect health in that PBC, as well as need for healthcare spending 
and environmental factors that affect health in other PBCs.  Health within each PBC is assumed to be 
a function of healthcare expenditure within that specific PBC only.   
This framework suggests the estimation of an expenditure equation (1) for each of the 23 PBCs, and 
an outcome equation (2) for the 10 PBCs for which mortality data are available.  
Accordingly, for the j-th PBC we have:
(1)𝑥𝑖= 𝛽0+ 𝛽1𝑛𝑖+ 𝛽2𝑚𝑖+ 𝛽3𝑦𝑖+ 𝜀𝑖
(2)ℎ𝑖= 𝛾0+ 𝛾1𝑛𝑖+ 𝛾2𝑥𝑖+ 𝜔𝑖
All variables are log-transformed prior to estimation in accordance with standard practice in this 
literature and consequently all coefficients are interpreted as elasticities. The  subscript denotes the 𝑖
unit of observation, (LA as opposed to PCT given data availability),  is the overall budget,  is 𝑦 ℎ
mortality in the j-th PBC,  is the expenditure on the j-th PBC,  is the need for healthcare in the j-th 𝑥 𝑛
PBC,   is the need for care in other PBCs,  and  arguments are parameters to be estimated (  is 𝑚 𝛽 𝛾 𝛽3
referred to as an ‘expenditure’ elasticity and  an ‘outcome’ elasticity), and  and  are error terms.𝛾2 𝜀 𝜔
It may be the case that  in equation 1 and  in equation 2 are endogenous, since other programme 𝑚 𝑥
need is proxied using the mortality rate in these other programmes, and expenditure in a disease 
area may be related to unobservable factors that influence the level of health outcomes (e.g. a high 
level of historical mortality).  For these reasons, the OLS estimation of equations 1 and 2 would likely 
result in bias even if the analysis controlled for observable healthcare need ( ).iv  One approach to 𝑛
controlling for this endogeneity is to use suitable instruments for the endogenous variables.3–7  
However, theory provides no guidance as to the specific IVs that should be used. In general, we need 
IVs that are associated with either PBC-specific expenditure or other-PBC mortality (this requirement 
is referred to as ‘instrument relevance’), but not PBC-specific mortality either directly or through 
iv Note that we instrument for   even though the coefficient of interest, , is estimated on .𝑚 𝛽3 𝑦












































































some unobserved variable (this requirement is referred to as ‘instrument validity’).  Instrument 
relevance can be directly tested, typically by requiring an F-test of excluded instruments in the first 
stage and requiring that the test statistic exceeds 10.10 Instrument validity cannot be directly tested, 
and expert judgement is required, but when an equation is over-identified (there are more excluded 
instruments than endogenous variables) then an over-identification test can be helpful, although it 
may lack power in rejecting the null hypothesis of joint validity in some circumstances.11
Each wave of data is analysed separately.  The preferred empirical specification for each PBC and for 
each year is identified using the following method.  We use the preferred empirical specifications 
reported by others5 for 2008/9 as the starting point for the estimation of outcome and expenditure 
equations for 2009/10.v  If the 2008/9 specification performs satisfactorily when re-estimated with 
20009/10 data, then this becomes our preferred specification for 2009/10 too.  A specification is 
deemed satisfactory if it passes a battery of statistical tests (including an endogeneity test, the 
Hansen-Sargan over-identification test, and the Kleibergen-Paap F test for instrument strength) and 
meets three priors: that expenditure reduces mortality ( ) and that expenditure on a given PBC 𝛾2< 0
increases with overall budget ( ) and decreases with other PBC need ( ).  𝛽3> 0 𝛽2< 0
If the specification fails a test then it is revised (to make good this failure) and re-estimated.  If this 
approach – of specification revision and re-estimation – fails to reveal an acceptable specification 
then the entire equation is re-estimated with covariates and instrumental variables using a 
backwards step-wise procedure.  In the rare circumstances where it proves impossible to obtain a 
satisfactory specification and outlier expenditure values are found, the sample is trimmed in an 
attempt to find an acceptable specification.vi  Further details of this estimation process are provided 
in the Appendix, section A1.1.
2.3 Translating mortality effects into quality-adjusted life-years
The outcome and expenditure elasticities obtained via the estimation of equations 1 and 2 for those 
10 PBCs with an outcome indicator, together with information about the number of life years lost in 
each programme, could be used to estimate the cost of a life year.3  The problem with such an 
estimate is that it would implicitly assume that expenditure in those programmes with a mortality 
indicator has no effect on morbidity, and that NHS expenditure on those programmes without a 
mortality indicator has no health effect at all.  These assumptions appear wholly implausible, 
especially when almost half of NHS expenditure is on programmes without a mortality indicator and 
morbidity is a significant aspect of disease burden where a mortality indicator is available.  
Complete morbidity and quality of life data by PBC and local area are not available, so direct 
estimates of a more comprehensive measure of the likely health effects of health expenditure (e.g., 
v FY 2010/11 then drew upon the preferred econometric specification from FY 2009/10, and so on, up to 
2012/13.  The model specification for 2008/09 drew upon that for FY 2009/10, and then that for FY 2007/08 
drew upon FY 2008/09 and so on until each an appropriate model was specified for each wave of data as far 
back as FY 2003/04 and up to FY 2012/13.
vi This was undertaken for 7 regression specifications out of a total of 310 reported as part of this paper (see 
Appendix 1 for more details).












































































QALY effects) are not possible. However, previous work has linked estimated effects on mortality to 
the likely QALY effects of changes in NHS healthcare expenditure using plausible assumptions. For 
example, one study5 drew on a number of data sources to estimate the QALY burden of disease for 
each 3 digit ICD10 code within each PBC.vii  They calculate the QALY burden of disease for each PBC 
by summing (over all relevant ICD10 codes) the product of the per patient QALY burden and the size 
of the population with the disease (prevalent and incident) in one year.  For each PBC with an 
outcome elasticity, the estimated change in its QALY burden associated with, say, a 1% change in the 
overall budget can be calculated by forming the product of the outcome elasticity, the expenditure 
elasticity, and the QALY burden for the PBC (i.e., effects on the mortality burden of disease are used 
as a ‘surrogate’ for effects on the broader QALY burden).  For those PBCs without an outcome 
indicator, this study5 calculates the average proportionate effect of a change in expenditure on the 
mortality burden of disease in those PBCs where mortality-based outcome elasticities can be 
estimated, and this average is used as a proxy for the outcome elasticity for those PBCs without a 
directly estimated outcome elasticity (the proportionate effects on burden of disease are 
extrapolated from where they can be observed to where they cannot).  
Therefore, using the same approach to estimating the QALY burden of disease, combined with these 
surrogacy and extrapolation assumptions, we are able to estimate the total QALY change associated 
with a change in total NHS expenditure for all PBCs and hence we can calculate the ‘cost per QALY’.  
Clearly, linking the estimated effects on mortality to QALYs requires a number of assumptions to be 
made.viii  Recently, the plausibility of these assumptions has been examined through structured 
elicitation from clinical experts29 and this work suggests that these assumptions are likely to be 
conservative with respect to the QALY effects of changes in expenditure (i.e., the cost per QALY is 
likely to be lower than that estimated using these assumptions).
3. Results
Full regression results for the preferred outcome and expenditure specifications by PBC for each 
year, including specification test results, can be found in the Appendix section A2.2, Tables A2.1 – 
A2.20.  The first stage regressions for the IV specifications can be found in the Appendix section 
A2.3, Tables A2.21 – A2.40.  Of particular interest are (i) the coefficients on the expenditure variables 
in the outcome equations and (ii) the coefficients on the budget variables in the expenditure 
equations.  These coefficients (elasticities) are presented in Table 1.ix
[Table 1 here]
vii Data from the WHO global burden of disease (GBD) study12 was used to estimate the duration and incidence 
of disease (by age and gender), ONS data provided mortality conditional life expectancies by age and gender, 
quality of life norms by age and gender were based on data from the Health Survey for England and the impact 
of disease on these quality of life norms were provided by Health Outcomes Data Repository (HODaR) 
supplemented with information from the Medical Expenditure Panel Survey (MEPS).
  
viii For a more detailed summary of all assumptions, their justification and a discussion of their likely impact on 
the central estimate of the cost per QALY see Table 32 on page 83 of this work5.
 
ix Note that cells containing “n/a” or “0” are not incomplete, but indicate that no elasticity was estimated for 
that PBC-year (or was estimated to be 0).












































































Taking cancer in 2012/13 as an illustrative example, the expenditure elasticity is interpreted as 
saying that a 1% increase in overall NHS expenditure leads to a 1.027% increase in cancer 
expenditure.  The outcome elasticity suggests that cancer mortality is reduced by 0.361% as a result 
of a 1% increase in cancer expenditure.  As outlined in section 2.3, these estimated elasticities can 
be combined with additional information about age, gender, life expectancy and burden of disease 
of the patient population to produce estimates of (i) the volume of resources used to produce a unit 
of health benefit (cost per QALY) and (ii) the volume of health benefits produced using a unit of 
resource (QALYs per £ of expenditure).  For the latter, we report the number of QALYs gained for 
£10 million, which represents a small amount of money relative to the overall level of NHS 
expenditure, and we label this the ‘health opportunity cost’ (HOC) associated with £10m of 
expenditure.  All estimates are expressed in current prices and are shown in Table 2.
[Table 2 here]
The cost per QALY and HOC estimates are generated first deterministically (column 1) and also 
probabilistically (columns 2 - 4). For the latter, draws are taken from independent Normal 
distributions for each outcome and expenditure elasticity with mean and variance equal to the 
estimated coefficient and standard error squared respectively. In total, 20,000 draws are made to 
generate a probability distribution for the overall result. The mean, 5th and 95th percentiles of the 
generated distributions are presented in Table 2.x  This confidence interval reflects sampling 
uncertainty and is determined entirely by the standard errors of the estimated expenditure and 
outcome elasticities.  The confidence interval does not reflect other sources of uncertainty arising 
from assumptions relating to the effect of expenditure on morbidity or any bias resulting from IV 
regressions with IVs that are not perfectly valid.
The numerical results shown in Table 2 are plotted in Figures 1 and 2. Figure 1 presents the 
deterministic point estimate for the cost per QALY along with its 90% confidence interval, while 
Figure 2 presents the deterministic point estimate in terms of the number of QALYs per £10 million 
of expenditure along with its 90% confidence interval. 
[Figure 1 here]
[Figure 2 here]
Figure 1 shows that all point estimates of the cost per QALY lie between £5,000 and £15,000, and 
Figure 2 shows that all point estimates for the HOC lie between 690 and 1,860 QALYs.  Although the 
point estimates are suggestive of an increase in the cost per QALY over the study period, the 
associated confidence intervals overlap each other considerably so that it is not obvious that there 
has been a significant change in the cost per QALY.  A similar argument can be made about the HOC.  
In addition, the HOC estimates do not decrease monotonically through time even though the cost 
figures are in current prices and NHS inflation averaged about 3% per annum during the study 
period.13 
x The deterministic and probabilistic point estimates differ because of the non-linear function that combines 
the estimated elasticities and additional information about survival and health-related quality of life. In 
particular, two features of the model are responsible for the non-linearity: the extrapolation assumption, and 
the adjustment to expenditure elasticities so that the changes in expenditure in all PBCs sum to the overall 
change in expenditure simulated (1% of total expenditure).













































































Claxton et al report a cost per QALY of between £10,000 and £15,000 for 2006/7, 2007/8 and 
2008/9.  This paper contributes to the literature by extending the number of years analysed and 
presents more recent estimates; our results suggest a cost per QALY of between £5,000 and £15,000 
for 2003/4 to 2012/13.  The extension of the study period is only possible by changing the unit of 
analysis to LA-level.  In addition, this paper uses more appropriate IVs by interpolating values from 
the 2001 and the 2011 censuses. Finally, this paper describes a process where additional waves of 
data can be added to the dataset and the preferred specification for the previous year can be used 
to inform the specification for the additional observation.
The results for 2012/13 (the most recent year) indicate that an additional £10mn of NHS expenditure 
generates 694 QALYs. Expressing this as a ratio of incremental cost to incremental health effect 
yields an estimate of the marginal productivity of NHS expenditure (£14,410 per QALY). However, as 
with most point estimates, there is uncertainty associated with it and we find that the 90% 
confidence interval for the cost per QALY ranges from £11,182 to £19,862.  As only the incremental 
health effect is estimated with uncertainty and this measure appears in the denominator of the (cost 
per QALY) ratio, the confidence interval is not symmetric around the point estimate.
While the reported point estimates should be used to calculate expected changes in health resulting 
from changes in expenditure, the degree of uncertainty in our estimates helps to assess the 
robustness of claims as to whether implicit or explicit established norms are compatible with this 
evidence or not. For example, since 2004, the National Institute for Health and Care Excellence 
(NICE), which issues guidance to the UK NHS, has published an explicit range for the cost-
effectiveness ‘thresholds’  used in its deliberative decision-making process: £20,000 per QALY to 
£30,000 per QALY.14  Although NICE makes clear that the ‘threshold’ ought to represent the health 
opportunity costs of the additional NHS costs of a new technology, this range was, in fact, founded 
on the values implied by the decisions it made between 1999 and 2003.15 The evidence from this 
paper suggests that the NHS’s marginal productivity is significantly higher (the cost per QALY is 
significantly lower) than that implied by NICE’s stated guidance.
An assessment of the marginal productivity of health care expenditure is of general policy interest 
beyond guidance for health technology appraisal.  For example, some judgement about the likely 
health effects of increasing or reducing public expenditure on health care is at the heart of debates 
about whether public expenditure should be increased to offer additional funding to the NHS or 
whether existing overall levels of public expenditure should be reallocated across spending 
departments.  The estimates presented above suggest that marginal increases in health expenditure, 
whether funded through additional taxation, borrowing or reallocation from other spending 
departments, appear good value when compared to estimates of the equivalent consumption value 
of health (with recent reviews suggesting that £30,000 per QALY might represent a reasonable lower 
bound for this).16,17  Where resource allocation decisions have been made on the implicit basis that 
the estimate of marginal productivity of the NHS is £30,000, or even £40,000 per QALY18, these 
decisions may have been sub-optimal in terms of population QALYs.19 QALYs may of course not be 
the sole objective of healthcare expenditure, and decisions may be made that lead to reductions in 
health (as measured by QALYs), but are judged worthwhile because of other considerations. A 
framework for analysis to inform decisions such as these is illustrated elsewhere.20












































































Similar studies from other healthcare systems vary widely in terms of methods used but produce 
similar results in the sense that the estimated marginal productivity is usually lower than the value 
implied by healthcare decision-makers.7,16,21,22 In this way our results are consistent with the existing 
literature with marginal productivity estimated to be much lower than currently explicitly stated 
norms23 or the values implied by actual decisions.18 
Looking at the results from this paper over time, the cost per QALY in 2012/13 is more than double 
that of 2003/04, but some of this will reflect input price inflation faced by the NHS, roughly 28% over 
the same period.13 Nevertheless, these results suggest that real productivity at the margin has fallen, 
which is consistent with diminishing marginal returns to health expenditure (expenditure has 
increased in nominal and real terms over most of the ten year period analysed24). Identifying factors 
that can explain this trend is difficult because there are many possible explanations for these 
changes, and it is left to future research to unpick the mechanisms underlying them.25
At the core of this analysis is the econometric estimation of expenditure and outcome elasticities.  A 
key component is the use of IVs to identify a causal effect. Our theoretical model does not tell us 
which instrumental variables should be used and the validity of those selected cannot always be 
tested.  Although for some PBCs there may be concern about the role of risk factors such as smoking 
and their association with socio-economic status, generally speaking the mechanisms of cause and 
effect underlying the observed associations between socio-economic status and PBC-specific 
mortalities are largely unknown.  Nevertheless, the likely presence of endogeneity suggests that we 
should attempt to use some econometric approach beyond OLS, such as IV regression, to obtain 
consistent estimates of the causal effects. As such we rely on an approach where we are guided by 
statistical tests in addition to a priori plausibility that instruments could be valid.  We have used 
appropriate statistical tests to guide model specification throughout, as part of a clearly specified 
and documented protocol before the analysis was undertaken (see Appendix A1.1). Nonetheless, the 
tests for validity can lack power to reject the null that IVs are appropriately excluded from the 
second stage of the IV regression, particularly when all IVs might be thought to influence the 
endogenous regressor in the same kind of way.11 
However, the results of the just-identified sensitivity analysis and the poor performance of an OLS 
strategy, reported in Appendix 1.2 and Appendix 1.3 respectively, combined with other related work 
provides greater confidence and insight into how these considerations might influence a reasonable 
interpretation of the results in this paper. Firstly, in related work5 a sensitivity analysis26,27 was 
undertaken to examine the impact of contaminated IVs (IVs that are not perfectly excluded from the 
second stage of the IV regression) which showed that contamination introduces additional 
uncertainty into the elasticity estimates, but not bias. Secondly, the implied all-cause elasticities 
using the approach taken to identification in this paper (see Appendix A1.2) are comparable with the 
directly estimated all-cause elasticities in the literature.6,28  The elasticities for key PBCs are also 
comparable.28 The fact that similar results are obtained when a very different approach to 
identification is taken generates confidence in the census-based instruments, that they are plausibly 
valid, and that the results are not highly specific local average treatment effects. This is especially 
important in the more common context where the identification strategy pioneered by Andrews et 
al (2017) is not possible. Taken together these considerations provide reassurance that our IV 
strategy is appropriate and that the estimates provided in this paper are not seemingly biased in a 
particular direction.  It also suggests that there is inevitably additional structural uncertainty that is 
not reflected in the confidence intervals reported in Table 2 and Figures 1 and 2.













































































Given the interest among economists in decision-making at the margin, and the longstanding 
interest in the productivity of publicly funded institutions like the NHS, it is surprising that so few 
studies have sought to estimate the marginal productivity of the NHS. Its usefulness is not limited to 
decisions within the healthcare sector but is essential to inform the allocation of scarce public 
resources across sectors too. This paper has shown how econometric analysis can be used to provide 
estimates of the marginal productivity of the NHS, with results expressed as either cost per QALY or 
QALYs per unit of expenditure. The results show that despite the inflation, the cost per QALY has 
remained relatively stable over time, with point estimates of the amount of resources, in nominal 
terms, to produce an additional unit of health benefit ranging from £5,000 to £15,000 per QALY over 
the period between 2003/04 and 2012/13.
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2003/04 2004/05 2005/06 2006/07 2007/08 2008/09 2009/10 2010/11 2011/12 2012/13
Outcome Spend Outcome Spend Outcome Spend Outcome Spend Outcome Spend Outcome Spend Outcome Spend Outcome Spend Outcome Spend Outcome Spend
Infectious 
diseases
-0.205 1.094*** -0.100 0.932*** -0.432 1.205*** -0.608 1.051*** -0.660** 1.387*** -0.549*** 1.471*** -0.310* 0.968*** -0.256 1.006*** -0.305*** 0.841*** -0.362*** 0.749***
Cancer -0.201** 1.711*** -0.224** 1.259*** -0.159* 1.592*** -0.239*** 1.219*** -0.273*** 1.626*** -0.287*** 0.784** -0.345*** 0.502** -0.220*** 0.438 -0.430*** 0.961** -0.361*** 1.027**
Blood n/a 0.652* n/a 0.952*** n/a 1.486*** n/a 1.037*** n/a 1.374*** n/a 0.995*** n/a 1.060*** n/a 0.332 n/a 0.876*** n/a 1.119***
Endocrine 0 0.653*** -1.843 0.573*** -1.035 0.663*** -1.464 0.630*** -1.491 0.455*** -1.607** 0.498*** -1.075** 0.708*** -0.174 0.696*** -0.199 1.116*** -0.499 0.951***
Mental health n/a 1.333*** n/a 0.999*** n/a 0.991*** n/a 1.143*** n/a 1.103*** n/a 0.995*** n/a 0.899*** n/a 0.973*** n/a 1.194*** n/a 1.023***
Learning disability n/a 0.646* n/a 0.446* n/a 0.449* n/a 0.410 n/a 0.386 n/a 0.329 n/a 0.647** n/a 1.208** n/a 0.741* n/a 0.000
Neurological -0.751* 1.408*** -0.968** 0.929*** -0.325 1.220*** -0.869* 0.382* -0.237* 0.733*** -0.304 0.897*** -1.357 0.850*** -0.374 0.557*** -1.415 0.703*** -0.009 0.856***
Vision n/a 0.833*** n/a 1.350*** n/a 1.127*** n/a 0.931*** n/a 1.106*** n/a 0.701*** n/a 0.934*** n/a 0.997*** n/a 1.279*** n/a 1.411***
Hearing n/a 0.694* n/a 0.526 n/a 0.762** n/a 0.989** n/a 0.951* n/a 1.637*** n/a 1.273*** n/a 0.808* n/a 1.231*** n/a 1.523***
Circulatory -1.202*** 1.873*** -1.375*** 1.652*** -1.637*** 1.477*** -1.404*** 1.578*** -1.315*** 1.614*** -1.384*** 1.784*** -1.842*** 0.494* -1.692*** 1.013*** -1.611*** 1.491*** -1.464*** 1.285***
Respiratory -1.666*** 1.661*** -2.494*** 1.253*** -2.217*** 1.225*** -2.281*** 1.287*** -1.564*** 1.555*** -1.671*** 0.752** -2.103*** 0.576*** -2.006** 1.192*** -1.743*** 1.360*** -1.704*** 0.928***
Dental n/a 0.717* n/a 0.848* n/a 1.224** n/a 0.835** n/a 0.420*** n/a 0.428** n/a 0.765*** n/a 0.229 n/a 0.843*** n/a 0.855***
Gastro-intestinal -1.493*** 1.409*** -1.253*** 0.928*** -1.014* 1.076*** -1.255** 1.014*** -0.837** 1.490*** -1.146** 0.520* -1.989* 0.387* -1.425** 1.040*** -2.000** 1.033*** -1.904** 0.997***
Skin n/a 0.700*** n/a 0.595*** n/a 0.840*** n/a 0.701*** n/a 0.787*** n/a 0.907*** n/a 0.890*** n/a 0.422* n/a 0.681*** n/a 1.158***
Musculo skeletal n/a 1.014*** n/a 0.567*** n/a 0.935*** n/a 0.628* n/a 0.733*** n/a 0.738*** n/a 0.295 n/a 0.489** n/a 0.456** n/a 0.725***
Trauma and 
injuries
0 0.556*** 0 0.576** 0 0.897*** 0 0.705*** -0.638 1.328*** 0 1.344*** 0 1.090*** -0.064 0.589** 0 1.024*** 0 1.058***
Genito-urinary -0.063 0.934*** -0.931* 0.716*** -0.869* 1.079*** -0.588 0.988*** -1.977 1.015*** -0.024 0.733*** -2.997 0.878*** -2.83 0.631*** -0.494 0.598*** -0.160 0.855***
Maternity and 
neonates
0 0.757*** -0.121 0.678*** -0.056 0.865*** -0.085 0.614** -0.057 0.563** -0.030 0.963*** -0.166* 0.653*** -0.04 0.342 -0.136 0.481*** -0.106 0.833***
Poisoning n/a 2.327*** n/a 1.674*** n/a 1.735*** n/a 1.107*** n/a 1.674*** n/a 2.102*** n/a 0.658** n/a 1.078** n/a 0.631** n/a 1.124***
Healthy 
individuals
n/a 1.538** n/a 0.709* n/a 0.507 n/a 0.709 n/a 1.296** n/a 1.049 n/a 1.246** n/a 1.359** n/a 1.748*** n/a 1.172*
Social care n/a 1.581*** n/a 1.313** n/a 1.069* n/a 1.702*** n/a 1.669** n/a 1.192* n/a 0.844 n/a 1.592** n/a 1.859*** n/a 1.613***
Other n/a 0.681*** n/a 0.337*** n/a 0.532*** n/a 0.447*** n/a 0.553*** n/a 0.338*** n/a 0.564*** n/a 0.520*** n/a 0.518*** n/a 0.585***
Note: *** denotes p<0.01, * denotes p<0.05, * denotes p<0.10
Table 1 - Estimated outcome and expenditure elasticities, by PBC, 2003/04 to 2012/13


































































5th percentile 95th percentile
Cost per QALY £6,381 £6,381 £5,048 £8,534
2003/04 Health opportunity 
costs of £10mn (QALYs)
1,567 1,567 1,172 1,981
Cost per QALY £5,389 £5,377 £4,110 £7,517
2004/05 Health opportunity 
costs of £10mn (QALYs)
1,856 1,860 1,330 2,433
Cost per QALY £7,613 £7,635 £5,611 £11,619
2005/06 Health opportunity 
costs of £10mn (QALYs)
1,314 1,310 861 1,782
Cost per QALY £6,844 £6,838 £5,139 £9,878
2006/07 Health opportunity 
costs of £10mn (QALYs)
1,461 1,462 1,012 1,946
Cost per QALY £9,747 £9,765 £7,689 £13,043
2007/08 Health opportunity 
costs of £10mn (QALYs)
1,026 1,024 767 1,301
Cost per QALY £12,960 £13,271 £8,390 £32,881
2008/09 Health opportunity 
costs of £10mn (QALYs)
772 754 304 1,192
Cost per QALY £9,887 £9,920 £6,802 £17,296
2009/10 Health opportunity 
costs of £10mn (QALYs)
1,011 1,008 578 1,470
Cost per QALY £10,225 £10,214 £7,073 £17,153
2010/11 Health opportunity 
costs of £10mn (QALYs)
978 979 583 1,414
Cost per QALY £8,997 £8,985 £6,520 £13,945
2011/12 Health opportunity 
costs of £10mn (QALYs)
1,112 1,113 717 1,534
Cost per QALY £14,410 £14,411 £11,182 £19,861
2012/13 Health opportunity 
costs of £10mn (QALYs)
694 694 504 894
Table 2 - Marginal productivity for 2003/04 to 2012/13











































































Figure 1 - Marginal productivity for 2003/04 to 2012/13 expressed as cost per QALY with 90% 
confidence intervals 
Figure 2 - Marginal productivity for 2003/04 to 2012/13 expressed as QALYs per £10 million with 
90% confidence intervals 
 














































































This Appendix is divided into two main sections, A1 and A2. 
The first part of the first section (A1.1) provides additional detail on the method used to identify our preferred 
specification for each outcome and expenditure equation reported in the main paper. The second and third parts 
of the first section (A1.2 and A1.3 respectively) contain two pieces of sensitivity analysis.  In A1.2, all of our 
preferred specifications are re-estimated using OLS.  We use the resulting outcome and expenditure elasticities to 
re-calculate the implied all-cause outcome elasticity for each of the study years. This (OLS-based) implied 
elasticity is typically much smaller (in absolute terms) than the implied all-cause outcome elasticity associated 
with our IV estimates.  The third part of the first section (A1.3) explores the impact of re-estimating our preferred 
outcome and expenditure specifications for the big four PBCs for 2012/13 using only a single instrument.  This is 
motivated by the idea that potential weak instrument bias can be mitigated to some extent by including only a 
single instrument (Angrist and Pischke, 2009). 
The second section of this appendix (section A2) provides the regression results for the preferred outcome and 
expenditure equations for each wave of data, in addition to the results of all relevant specification tests. 
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A1 Additional detail on methods
A1.1 Determining an appropriate econometric specification for each outcome and expenditure equation
The main paper briefly outlined our strategy for determining the appropriate econometric specification for each 
outcome and expenditure equation. This process is described in greater detail in this section.  
Each wave of data is analysed separately.  We use the preferred outcome and expenditure specifications for each 
PBC for 2008/9 as reported by Claxton et al (2015) as the starting point for the estimation of outcome and 
expenditure equations for 2009/10.  If the 2008/9 specification performs satisfactorily when re-estimated with 
20009/10 data, then this becomes our preferred specification for 2009/10 too.  A specification is deemed 
satisfactory if it passes a battery of statistical tests (including an endogeneity test, the Hansen-Sargan over-
identification test, and the Kleibergen-Paap F test for instrument strength) and meets three priors: that 
expenditure reduces mortality ( ) and that expenditure on a given PBC increases with overall budget (𝛾2< 0 𝛽3> 0
) and decreases with other PBC need ( ).  If the specification fails a test then it is revised (to make good this 𝛽2< 0
failure) and re-estimated.  If this approach – of specification revision and re-estimation – fails to reveal an 
acceptable specification then the entire equation is re-estimated with covariates and instrumental variables using 
a backwards step-wise procedure.  In the rare circumstances where it proves impossible to obtain a satisfactory 
specification and outlier expenditure values are found, the sample is trimmed in an attempt to find an acceptable 
specification.
This process -- of applying the preferred specification for the ‘current’ year to the next wave of data and adjusting 
the specification where necessary – is used to obtain preferred specifications for each PBC for 2009/10, 2010/11, 
2011/12 and 21012/13.  To get preferred specifications for each year back to 2003/4, we start with the preferred 
outcome and expenditure specifications for each PBC for 2009/10 and re-estimate them using data for 2008/9.  
These specifications are adjusted, if necessary, so that they pass the relevant statistical tests and meet our priors.  
This process -- of applying the preferred specification for the ‘current’ year to the previous wave of data and 
adjusting the specification where necessary – is used to obtain preferred specifications for each PBC for 2008/9, 
2007/8, and so on back to 2003/4.
For those readers seeking more detail, the following paragraphs describe more precisely how preferred 
specifications are identified, and Table A1.1 provides a qualitative indicator of the degree of adjustment required 
when moving from the preferred specification for one year to the preferred specification for the next year.
1. The preferred specification for the preceding year is used to re-estimate each outcome and expenditure 
equation for the year under consideration (if there is no precedent specification, this is denoted with a ‘*’ in Table 
A1.1). If this re-estimation produces a result which (a) passes the appropriate statistical tests and (b) generates 
coefficients in line with theoretical priors, use this result as our preferred result for the year under consideration.  
This rule is applied to cases where the preferred specification for the preceding year is either IV or OLS.  If this re-
estimation produces an acceptable result, this is denoted with a ‘--‘ in Table A1.1.
2. If the re-estimation produces a result which does not pass tests/have coefficients in line with priors, re-
estimate the equation having adjusted the specification as suggested by the initial result.  So, for example, if the 
initial estimation implies the presence of weak instruments and one of the instruments is insignificant in the first-
stage regression, try re-estimating the equation without the insignificant instrument. And if, for example, one of 
the regressors in the second-stage regression is insignificant, try re-estimating without it. If this re-estimation 
produces an acceptable result, this is denoted with a ‘A‘ in Table A1.1.













































































3. If a relatively minor adjustment to the preceding year’s specification does not generate a statistically and 
theoretically acceptable result, re-derive the IV equation to be estimated (again, this applies to cases where the 
preferred specification for the preceding year is either IV or OLS).  That is, use OLS with backward stepwise 
regression to identify relevant covariates to be included in the second-stage regression having forced in the 
relevant variables throughout.  For the outcome equation we force in own programme expenditure, and for the 
expenditure equation the other programme need variable and the total budget term are forced in throughout the 
stepwise procedure.
Having identified relevant covariates for the second-stage regression, again use stepwise backward regression to 
identify relevant instruments for the first-stage conditioning on the covariates for the second-stage identified 
above.  In other words, these second-stage covariates are forced in throughout stepwise procedure to identify 
relevant instruments.
Having identified covariates for the second-stage and instruments for the first-stage, re-estimate the IV 
specification equation using these two sets of variables.  If the endogeneity test suggests that a variable (eg own 
programme expenditure in the outcome equation) is clearly not endogenous then re-estimate using OLS.  If this 
re-estimation produces an acceptable result, this is denoted with a ‘B‘ in Table A1.1.
4. If the above re-estimation approach produces a result which does not pass tests/have coefficients in line with 
priors, re-estimate the equation having adjusted the specification as suggested by the initial result (for example,  
if the result fails the misspecification test try adding the squared value of one of the regressors to the 
specification).  If this re-estimation produces an acceptable result, this is denoted with a ‘C‘ in Table A1.1.
5. If the above approaches fail to produce an acceptable result, consider excluding LAs with extreme values of 
expenditure per person.  Only explore this option for programmes with small amounts of expenditure and/or 
mortality (e.g. by excluding the largest and smallest 5% of values or, very occasionally, by excluding obviously 
incorrect values).  If this re-estimation approach produces an acceptable result, this is denoted with a ‘D‘ in Table 
A1.1.
6. If all of the above fail then either use a value of zero if an outcome elasticity, or, if an expenditure elasticity, 
adopt the preceding wave's specification and use the estimate irrespective of test results and coefficients not 
conforming to priors. If this approach is used, it is denoted with a ‘E’ in Table A1.1.
Table A1.1 Type of specification adjustment undertaken when analysing next wave of data





















1 Infectious diseases A A A A -- -- A A A --
2 Cancers and tumours -- A -- -- A A A -- -- A
3 Diseases of the blood n/a B n/a A n/a -- n/a -- n/a --
4 Endocrine, nutritional, metabolic E A A A A -- A A D --
5 Mental health disorders n/a -- n/a -- n/a -- n/a -- n/a --
6 Learning disability n/a A n/a -- n/a D n/a B n/a --
7 Neurological problems A -- A -- A -- D A B A
8 Vision problems n/a -- n/a -- n/a -- n/a -- n/a C
9 Hearing problems n/a A n/a C n/a -- n/a -- n/a A
10 Circulatory problems -- -- A -- A -- -- -- A --
11 Respiratory problems -- -- A -- A A -- -- A A
12 Dental problems n/a A n/a E n/a E n/a C n/a D
13 Gastro-intestinal problems A -- -- -- -- -- -- A -- A
14 Skin problems n/a -- n/a A n/a A n/a A n/a --
15 Musculo-skeletal problems n/a -- n/a -- n/a -- n/a A n/a --
16 Trauma and injuries E A E A E A E -- * --
17 Genito-urinary problems B A -- A -- -- D A C A
18&19 Maternity and neonates E A -- A -- -- C -- A --













































































20 Poisoning and adverse events n/a -- n/a -- n/a -- n/a -- n/a A
21 Healthy individuals n/a A n/a A n/a B n/a B n/a C
22 Social care needs n/a A n/a -- n/a -- n/a -- n/a C
23 Other (includes GMS/PMS) n/a A n/a -- n/a -- n/a A n/a --
Key: (i) -- denotes the use of the same specification as the previous year; (ii) A – D indicate the severity of the adjustment to the previous specification with A 
denoting the most minor adjustment and D indicating the most severe (eg need to trim the sample to remove outliers); (iii) E indicates that no plausible 
specification could be found; and (iv) n/a denotes not applicable (no outcome measure available for this PBC). 
Table A1.1 continued Type of specification adjustment undertaken when analysing next wave of data





















1 Infectious diseases A -- A -- A -- B -- -- --
2 Cancers and tumours -- -- -- A -- -- A -- -- --
3 Diseases of the blood n/a -- n/a B n/a B n/a -- n/a --
4 Endocrine, nutritional, metabolic -- A A -- B C -- A B A
5 Mental health disorders n/a -- n/a -- n/a -- n/a -- n/a --
6 Learning disability n/a -- n/a B n/a C n/a D n/a B
7 Neurological problems C -- C -- C A C A B --
8 Vision problems n/a -- n/a A n/a -- n/a -- n/a --
9 Hearing problems n/a -- n/a C n/a -- n/a C n/a --
10 Circulatory problems -- A -- -- -- B -- -- -- A
11 Respiratory problems -- -- B -- A A -- A A --
12 Dental problems n/a B n/a B n/a B n/a C n/a B
13 Gastro-intestinal problems A -- A -- A A A A A --
14 Skin problems n/a -- n/a D n/a B n/a A n/a A
15 Musculo-skeletal problems n/a C n/a B n/a C n/a C n/a --
16 Trauma and injuries E -- E -- * A E A E --
17 Genito-urinary problems C -- B -- B A A -- C --
18&19 Maternity and neonates A -- B -- B -- A A -- --
20 Poisoning and adverse events n/a -- n/a -- n/a A n/a -- n/a --
21 Healthy individuals n/a -- n/a -- n/a A n/a -- n/a A
22 Social care needs n/a -- n/a B n/a -- n/a -- n/a A
23 Other (includes GMS/PMS) n/a -- n/a B n/a -- n/a A n/a --
Key: (i) -- denotes the use of the same specification as the previous year; (ii) A – D indicate the severity of the adjustment to the previous specification with A 
denoting the most minor adjustment and D indicating the most severe (eg need to trim the sample to remove outliers); (iii) E indicates that no plausible 
specification could be found; and (iv) n/a denotes not applicable (no outcome measure available for this PBC). 
A1.2 Sensitivity of the results to the assumption that expenditure is endogenous
The existing literature provides two estimates of the all-cause mortality elasticity for the English NHS: -0.71 
(Andrews et al. 2017) and -1.089 (Claxton et al. 2018).  Both of these estimates are for 2005/6 and assume that 
expenditure is endogenous in the outcome equation and employ an IV estimator. Both elasticities also result from 
the direct estimation of an all-cause outcome equation.
Although we do not directly estimate an all-cause outcome equation, the disease-specific outcome and 
expenditure elasticities reported in the main paper can be used to calculate an implied all-cause outcome 
elasticity.  This elasticity is presented in Table A1.2 together with the implied elasticity if all preferred 
specifications for all PBCs are re-estimated using OLS.




























































































Although the implied all-cause outcome elasticity is always negative using OLS, the (absolute) size of the OLS 
elasticity is always considerably less than the size of the IV-based elasticity.  Of course, the much smaller elasticity 
is to be expected with the use of OLS and the endogenous nature of expenditure. 
The implied all-cause elasticity for 2005/6 (=-1.372) is slightly larger (in absolute terms) than that reported for the 
same year from a directly estimated all-cause outcome equation by Andrews et al. (2017) and by Claxton et al. 
(2018).  This might be because an implied all-cause elasticity, which is based on component disease-specific 
elasticities, avoids the ‘aggregation bias’ inherent in a directly estimated all-cause elasticity.
To further illustrate the impact of using OLS rather than an IV estimator, Table A1.3 reports the outcome and 
expenditure elasticities for all of our preferred specifications for 2012/13 that were estimated using IVs.  These 
specifications were re-estimated using OLS and the relevant elasticities are also shown in A1.3. 
Table A1.3 PBC expenditure and outcome elasticities, 2012/13: main analysis and all OLS approaches 
PBC Expenditure equation Outcome equation
IV elasticity OLS elasticity IV elasticity OLS elasticity
Cancer 1.027** 0.220 -0.361*** -0.042
Circulatory 1.285*** 0.869*** -1.464*** -0.380***
Respiratory 0.928*** 0.602*** -1.704*** -0.121
Gastro-intestinal 0.997*** 0.656*** -1.904** -0.062
Endocrine 0.951*** 0.657*** -0.499 -0.409**
Neurological 0.856*** 0.474*** N/a (already OLS) N/a (already OLS)
Vision 1.411*** 0.923*** N/a N/a
Dental 0.855*** 0.737*** N/a N/a
Skin 1.158*** 0.704*** N/a N/a
Poisoning 1.124*** 0.588*** N/a N/a
*** p<0.01, ** p<0.05, * p<0.1













































































In all ten expenditure equations and all five outcome equations OLS generates smaller point estimates of the 
coefficient of interest. In addition, when using OLS, there is no evidence of a statistically significant effect of own-
PBC healthcare spending on cancer, respiratory and gastro-intestinal mortality.
A1.3 Sensitivity of IV results to just-identified IV approach
Recent theory suggests that potential weak instrument bias can be mitigated to some extent by including only a 
single instrument (Angrist & Pischke 2009).  To examine the impact of this approach on our results, we have re-
estimated those specifications that are over-identified, replacing the multiple instruments with only the strongest 
one.  Tables A1.6 and A1.7 report the results of this analysis for the ‘big four’ programmes using our preferred 
outcome and expenditure specifications for 2012/13 (note that variable names are described in section A2.1).  
These results are summarised in Tables A1.4 and A1.5.  
The preferred outcome equations for cancer and gastro-intestinal problems are already just identified.  Re-
estimation of the preferred outcome equations for circulatory disease and respiratory problems using only a 
single instrument reduces the absolute size of the outcome elasticity by just under 10%. 
Table A1.4
Programme budget category 2012/13 outcome elasticity Single instrument? 2012/13 outcome elasticity 
from preferred specification from preferred specification 
with single instrument
Cancer -0.361** Yes n/a
Circulatory disease -1.464*** No -1.332***
Respiratory problems -1.704*** No -1.538***
Gastro-intestinal -1.904** Yes n/a
The preferred expenditure equation for gastro-intestinal problems is already just identified.  Re-estimation of the 
preferred expenditure equation for the cancer programme increases the expenditure elasticity marginally, but re-
estimation has no effect on the elasticity in both the circulatory and respiratory PBCs.
Table A1.5
Programme budget category 2012/13 expenditure elasticity Single instrument? 2012/13 expenditure elasticity 
from preferred specification from preferred specification 
with single instrument
Cancer 1.027** No 1.052*
Circulatory disease 1.285*** No 1.285***
Respiratory problems 0.928*** No 0.928***
Gastro-intestinal 0.997*** Yes n/a
That the use of a single instrument has so little impact on our results is to be expected because we have avoided 
the use of multiple weak instruments in our preferred specifications.  
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Table A1.6 Re-estimation of preferred multi-instrument outcome specifications using only a single instrument for the big four programmes for 2012/13
(1) (2) (3) (4) (5) (6)
PBC 2 PBC 10 PBC 10 PBC 11 PBC 11 PBC 13
cancer circulatory circulatory respiratory respiratory gastro-intestinal
2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend
SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14
outcome model outcome model outcome model outcome model outcome model outcome model
instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend
weighted weighted weighted weighted weighted weighted
IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage
GM M 2S GM M 2S GM M 2S GM M 2S GM M 2S GM M 2S
LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 12 actual census 12 actual census 12 actual census 12 actual census 12 actual census 12
12/13 version 12/13 specification 12/13 specification 12/13 version 12/13 version 12/13 specification
VARIABLES preferred:one instrument preferred:two instruments one instrument preferred:two instruments one instrument preferred:one instrument
lLAg2_OHP -0.361**
[0.149]
lLAneedCARAN 1.023*** 2.304*** 2.226*** 3.878***





LPERM SICK 6.265*** 6.129***
[1.189] [1.200]






Constant 6.744*** 11.541*** 10.899*** 23.203*** 22.107*** 11.547***
[0.691] [1.302] [1.419] [3.903] [4.001] [4.024]
Observations 149 149 149 149 149 149
Endogeneity test statistic 8.481 30.621 26.263 20.193 21.300 8.574
Endogeneity p-value 0.004 0.000 0.000 0.000 0.000 0.003
Kleibergen-Paap LM  test statistic 10.435 24.067 20.885 19.742 18.916 10.507
Kleibergen-Paap p-value 0.001 0.000 0.000 0.000 0.000 0.001
Kleibergen-Paap F statistic 11.262 19.517 40.357 16.644 33.278 10.363
Pesaran-Taylor reset statistic 0.408 0.086 1.524 0.096 0.301 0.039
Pesaran-Taylor p-value 0.523 0.769 0.217 0.757 0.583 0.843
Hansen-Sargan test statistic 0.810 2.227
Hansen-Sargan p-value 0.368 0.136
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A1.7 Re-estimation of preferred multi-instrument expenditure specifications using only a single instrument for the big four programmes for 2012/13
(1) (2) (3) (4) (5) (6) (7)
PBC 2 PBC 2 PBC 10 PBC 10 PBC 11 PBC 11 PBC 13
cancer cancer circulatory circulatory respiratory respiratory gastro  problems
2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend
SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14
spend model spend model spend model spend model spend model spend model spend model
instrument o /need instrument o /need instrument o /need instrument o /need instrument o /need instrument o /need instrument o /need
weighted weighted weighted weighted weighted weighted weighted
IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage
GM M 2S GM M 2S GM M 2S GM M 2S GM M 2S GM M 2S GM M 2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census12 actual census12 actual census 12 actual census 12 actual census 12 actual census 12 actual census 12
12/13 specification 12/13 specification 12/13 specification 12/13 specification 12/13 specification 12/13 specification 12/13 specification
VARIABLES preferred:two instruments one instrument preferred:two instruments one instrument preferred:two instruments one instrument preferred:one instrument
lSYLLRacExCancer -1.565*** -1.569***
[0.326] [0.331]
lLAgall_OHP 1.027** 1.052* 1.285*** 1.285*** 0.928*** 0.928*** 0.997***







LNQUAL174 0.382*** 0.376*** 0.408*** 0.408*** 0.357***









Constant 5.169 4.998 1.110 1.231 0.296 0.295 0.942
[3.768] [4.240] [0.993] [1.014] [0.744] [0.746] [0.872]
Observations 149 149 149 149 149 149 149
Endogeneity test statistic 28.098 26.230 12.964 15.021 6.507 6.481 7.495
Endogeneity p-value 0.000 0.000 0.000 0.000 0.011 0.011 0.006
Hansen-Sargan test statistic 0.008 2.162 0.000
Hansen-Sargan p-value 0.929 0.141 0.985
Kleibergen-Paap LM  test statistic 18.904 18.899 31.331 27.198 23.711 23.540 29.937
Kleibergen-Paap p-value 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Kleibergen-Paap F statistic 18.752 37.971 65.251 98.789 23.538 47.153 122.358
Pesaran-Taylor reset statistic 2.365 2.213 0.808 1.271 0.483 0.363 0.024
Pesaran-Taylor p-value 0.124 0.137 0.369 0.260 0.487 0.547 0.878
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1































































A2 Results for specific equations underpinning main results
In this section we provide the regression results for the preferred outcome and expenditure 
equations for each wave of data, in addition to the results of all relevant specification tests. 
A2.1 Description of variables 
The census based variables used in this study have the following names:
Short variable 
name Long variable name
BORNEXEU Proportion of residents born outside the European Union
WHITEEG Proportion of population in white ethnic group
PCWALLTI
Proportion of population of working age (16-74) with a limiting 
long-term illness
POPPUCAR Proportion of population providing unpaid care
NQUAL174 Proportion of population aged 16-74 with no qualifications
HHNOCAR Proportion of households without a car
OWNOCC Proportion of owner occupied households
LONEPENH Proportion of lone pensioner households
LONEPARH Proportion of one parent households
PERMSICK Proportion of population aged 16-74 that are permanently sick
PC74LTUN
Proportion of population aged 16-74 are long-term 
unemployed
WORKAGRI Proportion of 16-74 in employment that are in agriculture
PROFOCCU
Proportion of those aged 16-74 that are in professional 
occupations
The short variable names are augmented with both a prefix and suffix in the preferred specifications 
reported below.  An ‘L’ in the prefix denotes that the log value of the variable has been used in the 
estimation, and the numeric suffix denotes the year to which the variable relates.   To obtain values 
for non-census years we interpolated values between the 2001 and 2011 censuses.  We used census 
values for 2011 when estimating specifications for 2012. 
Other (non-census based) indicators used in this study include:  
IMD2007 Index of Multiple Deprivation 2007
IMD2010 Index of Multiple Deprivation 2010
needCARAN
Need index (incorporates CARAN or other relevant needs 
formula)
DIAPREV Diabetes prevalence rate
EPIPREV Epilepsy prevalence rate
HIVNEEDPH HIV need index 
CKDPREV Chronic kidney disease prevalence rate
MATNEEDPP Maternity need index
As is the case for the census-based variables, the short variable names for these other indicators are 
augmented with both a prefix and suffix in the preferred specifications reported below.  An ‘L’ in the 













































































prefix denotes that the log value of the variable has been used in the estimation, and the numeric 
suffix denotes the year to which the variable relates.   Thus ‘lLAhivneedph’ denotes the log of the 
value of the HIV need index at local authority level.  Sometimes, specifications ‘fail’ the reset test 
and we add the square of one of the indicators.  These variables are denoted either with a ‘2’ as a 
suffix (for example, ‘lLAhivneedph2’ is the square of the HIV need index, and ‘lLAneedCARAN342’ is 
the square of the need index for 2003/4) or with `SQ’ as a suffix (for example, ‘LPERMSICK07SQ’ is 
the square of the ‘permanently sick’ variable for 2007).
The programme specific expenditure variables have names like ‘lLAg1_34’ where ‘l’ denotes that the 
log value has been used, ‘LA’ denotes that expenditure has been mapped to a local authority 
geography, ‘g1’ denotes expenditure in PBC 1, and ‘34’ denotes expenditure in the financial year 
2003/4. The variable name ‘lLAgall_34’ relates to expenditure across all PBCs in 2003/4.  Sometimes, 
we combine expenditure across two PBCs.  Thus the variable name ‘lLAg1819_78’ relates to 
expenditure across PBC 18 and PBC 19 combined in 2007/8.
The mortality variables have names like ‘lSYLLRallcause345’ where ‘l’ denotes that the log value has 
been used, ‘SYLLR’ denotes that the standardised years of life lost rate has been used, ‘all cause’ 
relates to the disease coverage, and ‘345’ denotes that the data relate to 2003, 2004, and 2005 
combined.  A further example is ‘lSYLLRacExIandP345’; this is a proxy for ‘other PBC need’ in the 
expenditure equation for the infectious and parasitic diseases PBC and ‘acExIandP’ refers to all-cause 
mortality excluding infectious and parasitic diseases.  Another example is ‘lSYLLRacExDIA345’; this is 
a proxy for ‘other PBC need’ in the expenditure equation for the diabetes PBC, and ‘acExDIA’ refers 
to all-cause mortality excluding diabetes.
All regressions are weighted regressions where analytical weights are constructed using the 
populations of the LAs.  
Descriptive statistics for 2012/13 for a selection of variables employed in the analysis are shown in 
Table A2.0 below.  There are 151 observations for each variable and, with the exception of the infant 
mortality rate, all mortality rates refer to the standardised years of life lost rate per 10,000 of 
European standard population.  Average NHS expenditure per person on healthcare is £1,839.  On 
average, 13% of all residents are born outside the European Union, 31% of the working-age 
population are employed in managerial and professional occupations, and 62% of households are 
owner occupied.  However, these averages mask considerable variation across local authorities: the 
proportion of residents born outside the EU varies from under 2% to more than 50%, and the extent 
of owner occupation ranges between 26% and 81% of all households.


















































































Expenditure per person (£) 1838.84 245.2 1420.48 2656.33
Raw population 350905 265305 11743 1438699
Mortality rates
Infectious and parasitic disease mortality 6.24 2.7 0 14.45
Cancer mortality 160.86 20.78 93.63 207.91
Diabetes mortality 4.12 1.67 0.25 9.48
Epilepsy mortality 3.71 1.68 0 9.64
Circulatory disease mortality 88.09 19.76 43.2 141.77
Respiratory mortality 25.24 8.88 10.8 57.47
Gastro-intestinal mortality 24.01 9.97 0 61.8
Renal mortality 0.46 0.38 0 2.1
Infant (28 day) mortality rate 2.69 0.83 0 5.5
Socio-economic variables
Proportion of all residents born outside the European Union 0.129 0.115 0.014 0.506
Proportion of population in white ethnic group 0.835 0.163 0.290 0.985
Proportion of population providing unpaid care 0.101 0.014 0.065 0.129
Proportion of population aged 16-74 with no qualifications 0.247 0.060 0.072 0.387
Proportion of households without a car 0.285 0.124 0.090 0.694
Proportion of households that are owner occupied 0.620 0.114 0.261 0.809
Proportion of households that are one pensioner households 0.120 0.021 0.060 0.167
Proportion of households that are lone parent households with dependent children 0.075 0.018 0.021 0.144
Proportion of population aged 16-74 that are permanently sick 0.043 0.015 0.016 0.088
Proportion of those aged 16-74 that are long-term unemployed 0.018 0.006 0.009 0.037
Proportion of those aged 16-74 in employment that are working agriculture 0.006 0.009 0.000 0.054
Proportion of those aged 16-74 in managerial and professional occupations 0.312 0.077 0.183 0.667
Index of Multiple Deprivation, 2010 23.112 8.62 5.445 43.447













































































A2.2 Second stage of IV regressions and OLS regressions results tables
Table A2.1 Preferred outcome specifications for 2003/04
Table A2.2 Preferred expenditure specifications for 2003/04
Table A2.3 Preferred outcome specifications for 2004/05
Table A2.4 Preferred expenditure specifications for 2004/05
Table A2.5 Preferred outcome specifications for 2005/06
Table A2.6 Preferred expenditure specifications for 2005/06
Table A2.7 Preferred outcome specifications for 2006/07
Table A2.8 Preferred expenditure specifications for 2006/07
Table A2.9 Preferred outcome specifications for 2007/08
Table A2.10 Preferred expenditure specifications for 2007/08
Table A2.11 Preferred outcome specifications for 2008/09
Table A2.12 Preferred expenditure specifications for 2008/09
Table A2.13 Preferred outcome specifications for 2009/10
Table A2.14 Preferred expenditure specifications for 2009/10
Table A2.15 Preferred outcome specifications for 2010/11
Table A2.16 Preferred expenditure specifications for 2010/11
Table A2.17 Preferred outcome specifications for 2011/12
Table A2.18 Preferred expenditure specifications for 2011/12
Table A2.19 Preferred outcome specifications for 2012/13
Table A2.20 Preferred expenditure specifications for 2012/13
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Table A2.1 Preferred outcome specifications for 2003/04
 (1) (2) (3) (4) (5) (6) (7)
PBC 1 PBC 2 PBC 7 PBC 10 PBC 11 PBC 13 PBC 17
infectious cancer neurological circulatory respiratory gastro genito-urinary
2003/4 spend 2003/4 spend 2003/4 spend 2003/4 spend 2003/4 spend 2004/5 spend 2003/4 spend
SYLLR 2003/4/5 SYLLR 2003/4/5 SYLLR 2003/4/5 SYLLR 2003/4/5 SYLLR 2003/4/5 SYLLR 2003/4/5 SYLLR 2003/4/5
outcome model outcome model outcome model outcome model outcome model outcome model outcome model
instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend
weighted weighted weighted weighted weighted weighted weighted
IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage
GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 03 actual census 03 actual census 03 actual census 03 actual census 03 actual census 03 actual census 03
VARIABLES 04/05 revised 04/05 specification 04/05 revised 04/05 specification 04/05 specification 04/05 revised re-derived













lLAneedCARAN34 0.750*** 0.716** 3.748*** 0.321






































































Constant -1.843* 5.893*** 3.239** 12.254*** 9.747*** 12.635*** 1.263
[1.082] [0.393] [1.296] [1.023] [1.777] [2.414] [2.895]
Observations 144 151 135 151 151 151 151
Endogeneity test statistic 0.928 4.945 2.165 32.851 28.292 11.906 0.038
Endogeneity p-value 0.336 0.026 0.141 0.000 0.000 0.001 0.846
Kleibergen-Paap LM test statistic 7.931 16.583 12.542 19.283 13.403 14.162 17.836
Kleibergen-Paap p-value 0.005 0.000 0.002 0.000 0.000 0.000 0.000
Kleibergen-Paap F statistic 9.795 10.257 10.043 55.862 28.447 24.260 24.694
Pesaran-Taylor reset statistic 0.641 0.047 0.834 0.009 1.210 0.000 0.177
Pesaran-Taylor p-value 0.423 0.828 0.361 0.924 0.271 0.995 0.674
Hansen-Sargan test statistic 0.971 0.501
Hansen-Sargan p-value  0.324 0.479     
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.2 Preferred expenditure specifications for 2003/04
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10)
PBC 1 PBC 2 PBC 3 PBC 4 PBC 5 PBC 6 PBC 7 PBC 8 PBC 9 PBC 10
infectious cancer blood endocrine mental health LDisability neurological vision hearing circulatory
2003/4 spend 2003/4 spend 2003/4 spend 2003/4 spend 2003/4 spend 2003/04 spend 2003/04 spend 2003/4 spend 2003/4 spend 2003/4 spend
SYLLR 2003/4/5 SYLLR 2003/4/5 SYLLR 2003/4/5 SYLLR 2003/4/5 SYLLR 2003/4/5/ SYLLR 2003/04/05 SYLLR 2003/04/05 SYLLR 2003/4/5 SYLLR 2003/4/5 SYLLR 2003/4/5
spend model spend model spend model spend model spend model spend model spend model spend model spend model spend model
instrument n/a instrument o/need instrument n/a instrument n/a instrument n/a instrument n/a instrument n/a instrument o/need instrument o/need instrument o/need
weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted
OLS IV second stage OLS OLS OLS OLS OLS IV second stage IV second stage IV second stage
GMM2S GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 03 actual census 03 actual census 03 actual census 04 actual census 03 actual census 03 actual census 03 actual census 03 actual census 03 actual census 03
VARIABLES 04/05 revised 04/05 specification re-derived OLS 04/05 revised 04/05 specification 04/05 revised 04/05 specification 04/05 specification 04/05 revised 04/05 specification
           
lLAgall_34 1.094*** 1.711*** 0.652* 0.653*** 1.333*** 0.646* 1.408*** 0.833*** 0.694* 1.873***











lSYLLRallcause345 0.321 -0.155 0.204 -0.612** 0.768




















































































Constant -4.412*** -2.084 -3.602 0.584 -4.828*** -2.782 -1.831 2.111* -11.683*** 3.212**
[1.181] [1.347] [2.926] [0.797] [1.559] [2.716] [1.298] [1.225] [3.401] [1.305]
Observations 147 151 150 149 151 137 151 151 151 151
R-squared 0.623 0.244 0.366 0.665 0.098 0.330
Ramsey reset F statistic 1.280 1.021 2.043 1.403 0.678 0.144
Probability > F 0.284 0.386 0.111 0.244 0.567 0.934
Endogeneity test statistic 9.775 3.979 0.261 21.240
Endogeneity p-value 0.002 0.046 0.609 0.000
Kleibergen-Paap LM test statistic 26.685 31.247 20.340 23.015
Kleibergen-Paap p-value 0.000 0.000 0.000 0.000
Kleibergen-Paap F statistic 45.579 35.891 28.335 19.117
Pesaran-Taylor reset statistic 0.185 0.437 0.580 1.931
Pesaran-Taylor p-value 0.667 0.509 0.446 0.165
Hansen-Sargan test statistic 0.101 0.129 0.288
Hansen-Sargan p-value        0.751 0.720 0.592
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.2 continued  Preferred expenditure specifications for 2003/04
 (1) (2) (3) (4) (5) (6) (7) (8) (9)
PBC 11 PBC 12 PBC 13 PBC 14 PBC 15 PBC 16 PBC 17 PBC 1819 PBC 20
respiratory dental gastro skin problems musculo-skeletal trauma genito- mat/neonates poisoning
2003/4 spend 2003/4 spend 2004/5 spend 2003/04 spend 2003/04 spend 2003/4 spend 2003/4 spend 2003/04 spend 2003/4 spend
SYLLR 2003/4/5 SYLLR 2003/4/5 SYLLR 2004/5/6 SYLLR 2003/4/5 SYLLR 2003/4/5 SYLLR 2003/4/5 SYLLR 2003/4/5 infant mort rate 2003/04/05 SYLLR 2003/4/5
spend model spend model spend model spend model spend model spend model spend model spend model spend model
instrument o/need instrument n/a instrument o/need instrument n/a instrument n/a instrument n/a instrument n/a o/need exogenous instrument o/need
weighted weighted weighted weighted weighted weighted weighted weighted weighted
IV second stage OLS IV second stage OLS OLS OLS OLS OLS IV second stage
GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 03 actual census 03 actual census 03 actual census 04 actual census 03 actual census 03 actual census 03 actual census 03 actual census 03
VARIABLES 04/05 specification 04/05 1/99 specification 04/05 specification 04/05 revised 04/05 specification 04/05 revised 04/05 revised 04/05 revised 04/05 specification
          
lSYLLRallcause345 0.736 0.131 -0.327** 0.091 0.136 -1.909***
[0.448] [0.113] [0.164] [0.122] [0.230] [0.412]
lLAgall_34 1.661*** 0.717* 1.409*** 0.700*** 1.014*** 0.556*** 0.934*** 0.757*** 2.327***
[0.217] [0.390] [0.219] [0.128] [0.176] [0.155] [0.193] [0.237] [0.413]
LPOPPUCAR03 0.823*
[0.454]
LNQUAL17403 0.605*** -0.878*** 0.706*** 0.178** 0.860***



















Constant -1.549 -6.011** 2.171* -2.418*** -2.161 0.783 -2.077** -1.977 -1.079
[1.126] [2.659] [1.212] [0.859] [1.684] [0.900] [0.921] [1.790] [1.587]
Observations 151 147 151 151 151 151 151 151 151
R-squared 0.133 0.391 0.265 0.346 0.498 0.326
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Endogeneity test statistic 10.155 9.194 9.308
Endogeneity p-value 0.001 0.002 0.002
Kleibergen-Paap LM test statistic 26.355 25.192 30.213
Kleibergen-Paap p-value 0.000 0.000 0.000
Kleibergen-Paap F statistic 48.934 96.403 35.169
Pesaran-Taylor reset statistic 0.177 0.021 0.010
Pesaran-Taylor p-value 0.674 0.886 0.919
Ramsey reset F statistic 1.802 1.640 0.560 1.379 1.993 0.301
Probability > F 0.150 0.183 0.642 0.251 0.118 0.824
Hansen-Sargan test statistic 0.584
Hansen-Sargan p-value         0.445
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1

















































CONFIDENTIAL - NOT FOR DISTRIBUTION
19
Table A2.2 continued  Preferred expenditure specifications for 2003/04
 (1) (2) (3)
PBC 21 PBC 22 PBC 23
HI social care GMS
2003/4 spend 2003/04 spend 2003/4 spend
SYLLR 2003/04/05 SYLLR 2003/04/05 SYLLR 2003/4/5
spend model spend model spend model
instrument o/need o/need exogenous instrument n/a
weighted weighted weighted
IV second stage OLS OLS
GMM2S
LA-level LA-level LA-level
actual mortality actual mortality actual mortality
actual census 03 actual census 03 actual census 03
VARIABLES 04/05 IV revised 04/05 revised 04/05 revised
    
lSYLLRallcause345 -2.190** -1.539*** -0.117
[0.983] [0.381] [0.116]






Constant 8.683 1.534 0.831
[5.661] [2.555] [0.876]
Observations 151 148 151
R-squared 0.093 0.297
Endogeneity test statistic 7.348
Endogeneity p-value 0.007
Hansen-Sargan test statistic 3.994
Hansen-Sargan p-value 0.136
Kleibergen-Paap LM test statistic 32.122
Kleibergen-Paap p-value 0.000
Kleibergen-Paap F statistic 19.387
Pesaran-Taylor reset statistic 0.000
Pesaran-Taylor p-value 0.985
Ramsey reset F statistic 2.020 0.584
Probability > F  0.114 0.627
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.3 Preferred outcome specifications for 2004/05
 (1) (2) (3) (4) (5) (6) (7) (8) (9)
PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13 PBC 17 PBC 1819
infectious cancer endocrine neurological circulatory respiratory gastro genito- mat/neonates
2004/5 spend 2004/5 spend 2004/5 spend 2004/5 spend 2004/5 spend 2004/5 spend 2004/5 spend 2004/5 spend 2004/05 spend
SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/5/6 inf mort rate 2004/05/06
outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model
instrument n/a instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend instrument n/a spend exogenous
weighted weighted weighted weighted weighted weighted weighted weighted weighted
OLS IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage OLS OLS
GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 actual census 04
VARIABLES 05/06 revised 05/06 specification 05/06 revised 05/06 revised 05/06 revised 05/06 revised 05/06 specification 05/06 revised 05/06 specification
          
lLAhivneedph 0.112**
[0.054]
lLAimd_2007exexpobook 0.282*** 0.667*** 0.503*** 0.235***









lLAneedCARAN45 0.778*** 1.223*** 4.895*** 3.466***
















































































Constant 1.106*** 6.008*** 8.364** 4.082** 12.804*** 13.346*** 8.469*** 5.829** 1.210*
[0.344] [0.481] [3.974] [1.722] [1.042] [3.439] [1.872] [2.597] [0.631]
Observations 145 151 136 137 151 151 151 137 151
R-squared 0.565 0.211 0.457
Ramsey reset F statistic 0.698 0.803 1.023
Probability > F 0.555 0.494 0.384
Endogeneity test statistic 2.886 3.349 2.863 30.641 26.954 6.925
Endogeneity p-value 0.089 0.067 0.091 0.000 0.000 0.009
Hansen-Sargan test statistic 0.297 0.880
Hansen-Sargan p-value 0.586 0.348
Kleibergen-Paap LM test statistic 14.712 7.045 16.830 21.333 7.554 16.801
Kleibergen-Paap p-value 0.001 0.008 0.000 0.000 0.006 0.000
Kleibergen-Paap F statistic 9.441 10.808 14.107 67.065 13.553 33.424
Pesaran-Taylor reset statistic 2.454 2.713 2.393 0.150 0.551 0.534
Pesaran-Taylor p-value  0.293 0.100 0.122 0.699 0.458 0.465   
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.4 Preferred expenditure specifications for 2004/05
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10)
PBC 1 PBC 2 PBC 3 PBC 4 PBC 5 PBC 6 PBC 7 PBC 8 PBC 9 PBC 10
infectious cancer blood endocrine mental health LDisability neurological vision hearing circulatory
2004/5 spend 2004/5 spend 2004/5 spend 2004/5 spend 2004/5 spend 2004/05 spend 2004/05 spend 2004/5 spend 2004/5 spend 2004/5 spend
SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/05/06 SYLLR 2004/05/06 SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/5/6
spend model spend model spend model spend model spend model spend model spend model spend model spend model spend model
instrument n/a instrument o/need instrument n/a instrument n/a instrument n/a instrument n/a instrument n/a instrument o/need instrument o/need instrument o/need
weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted
OLS IV second stage OLS OLS OLS OLS OLS IV second stage IV second stage IV second stage
GMM2S GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 actual census 04
VARIABLES 05/06 revised 05/06 specification 05/06 revised 05/06 revised 05/06 specification 5/6 specification 5/6 specification 05/06 specification re-derived+ 05/06 specification
           
lLAgall_45 0.932*** 1.259*** 0.952*** 0.573*** 0.999*** 0.446* 0.929*** 1.350*** 0.526 1.652***













lSYLLRallcause456 -0.027 -0.108 -0.154 -0.825*** 0.870
[0.203] [0.154] [0.211] [0.293] [0.540]











































































Constant -2.947*** 3.265* -4.090** 0.224 -3.165* 1.448 -0.206 -0.380 -6.905* 2.137**
[1.015] [1.973] [1.814] [0.792] [1.786] [1.613] [1.367] [1.119] [3.779] [1.064]
Observations 145 151 151 151 151 137 151 151 151 151
R-squared 0.584 0.371 0.369 0.667 0.073 0.200
Ramsey reset F statistic 0.330 0.444 1.478 1.235 0.612 1.654
Probability > F 0.803 0.722 0.223 0.299 0.609 0.180
Endogeneity test statistic 13.951 4.380 0.049 18.772
Endogeneity p-value 0.000 0.036 0.825 0.000
Kleibergen-Paap LM test statistic 14.760 35.712 29.992 25.947
Kleibergen-Paap p-value 0.000 0.000 0.000 0.000
Kleibergen-Paap F statistic 14.608 41.912 40.253 23.031
Pesaran-Taylor reset statistic 0.442 0.123 0.044 0.024
Pesaran-Taylor p-value 0.506 0.726 0.835 0.877
Hansen-Sargan test statistic 2.023 1.404 1.474
Hansen-Sargan p-value        0.155 0.236 0.225
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.4 continued  Preferred expenditure specifications for 2004/05
 (1) (2) (3) (4) (5) (6) (7) (8)
PBC 11 PBC 13 PBC 14 PBC 15 PBC 16 PBC 17 PBC 1819 PBC 20
respiratory gastro skin problems musculo-skeletal trauma genito- mat/neonates poisoning
2004/5 spend 2004/5 spend 2004/05 spend 2004/05 spend 2004/5 spend 2004/5 spend 2004/05 spend 2004/5 spend
SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/5/6 infant mort rate 2004/05/06 SYLLR 2004/5/6
spend model spend model spend model spend model spend model spend model spend model spend model
instrument o/need instrument o/need instrument n/a instrument n/a instrument n/a instrument n/a o/need exogenous instrument o/need
weighted weighted weighted weighted weighted weighted weighted weighted
IV second stage IV second stage OLS OLS OLS OLS OLS IV second stage
GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 actual census 04
VARIABLES 05/06 specification 05/06 specification 05/06 specification 05/06 specification 05/06 revised 05/06 revised 05/06 revised 05/06 specification
         
lSYLLRacExResp456 -0.377*
[0.205]
lLAgall_45 1.253*** 0.928*** 0.595*** 0.567*** 0.576** 0.716*** 0.678*** 1.674***
[0.186] [0.167] [0.203] [0.164] [0.235] [0.242] [0.156] [0.297]
LNQUAL17404 0.430*** 0.467*** 0.176* 0.706***
[0.080] [0.066] [0.101] [0.142]
lSYLLRacExGast456 -0.399**
[0.203]
lSYLLRallcause456 0.114 -0.023 -0.244 -0.025 -1.414***

















Constant -1.899** 0.749 -1.639 -1.025 1.679 3.734 -0.983 0.219
[0.802] [0.746] [1.055] [1.468] [1.957] [2.268] [0.998] [1.395]
Observations 151 151 151 151 151 151 151 151
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Endogeneity test statistic 5.586 1.528 12.795
Endogeneity p-value 0.018 0.216 0.000
Kleibergen-Paap LM test statistic 28.181 33.441 33.481
Kleibergen-Paap p-value 0.000 0.000 0.000
Kleibergen-Paap F statistic 58.442 112.795 40.539
Pesaran-Taylor reset statistic 0.021 0.845 1.118
Pesaran-Taylor p-value 0.885 0.358 0.290
Hansen-Sargan test statistic 1.316
Hansen-Sargan p-value 0.251
R-squared 0.362 0.249 0.363 0.366 0.523
Ramsey reset F statistic 1.547 1.891 0.676 1.843 1.850
Probability > F   0.205 0.134 0.568 0.142 0.141  
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1

















































CONFIDENTIAL - NOT FOR DISTRIBUTION
26
Table A2.4 continued  Preferred expenditure specifications for 2004/05
 (1) (2) (3)
PBC 21 PBC 22 PBC 23a
HI social care GMS
2004/05 spend 2004/05 spend 2004/5 spend
SYLLR 2004/05/06 SYLLR 2004/05/06 SYLLR 2004/5/6
spend model spend model spend model




actual mortality actual mortality actual mortality
actual census 04 actual census 04 actual census 04
VARIABLES 05/06 revised OLS 05/06 OLS 05/06 specification
    






lSYLLRallcause456 0.323 -0.940** 0.071
[0.277] [0.427] [0.062]
Constant -4.176** -0.206 2.166***
[1.881] [3.050] [0.487]
Observations 151 98 146
R-squared 0.174 0.076 0.259
Ramsey reset F statistic 1.780 1.085 1.314
Probability > F 0.154 0.360 0.272
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.5 Preferred outcome specifications for 2005/06
 (1) (2) (3) (4) (5) (6) (7) (8) (9)
PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13 PBC 17 PBC 1819
infectious cancer endocrine neurological circulatory respiratory gastro genito- mat/neonates
2005/6 spend 2005/6 spend 2005/6 spend 2005/6 spend 2005/6 spend 2005/6 spend 2005/6 spend 2005/6 spend 2005/06 spend
SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 infant mort rate 2005/6/7
outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model
instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend instrument n/a spend exogenous
weighted weighted weighted weighted weighted weighted weighted weighted weighted
IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage OLS OLS
GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05
VARIABLES 6/7 specification 06/07 revised 06/07 specification 6/7 revised+ 06/07 revised+ 06/07 revised 06/07 specification 6/7 revised 5/95% rederived OLS







lLAimd_2007exexpobook 0.372*** 0.629*** 0.223** 0.158**
[0.097] [0.149] [0.102] [0.070]
lLAg2_56 -0.159*
[0.086]
lLAneedCARAN56 0.758*** 0.901** 4.676*** 3.416***






















































































Constant 2.241** 5.730*** 6.349 14.837 14.726*** 12.403*** 7.559*** -0.941 1.289**
[0.925] [0.381] [4.263] [10.345] [1.927] [3.496] [2.294] [2.829] [0.608]
Observations 149 151 136 136 151 151 151 136 151
R-squared 0.228 0.407
Endogeneity test statistic 1.680 3.078 0.937 1.490 28.751 20.370 6.411
Endogeneity p-value 0.195 0.079 0.333 0.222 0.000 0.000 0.011
Kleibergen-Paap LM test statistic 12.475 18.668 8.162 20.976 14.371 7.453 16.180
Kleibergen-Paap p-value 0.000 0.000 0.004 0.000 0.001 0.006 0.000
Kleibergen-Paap F statistic 19.089 15.860 9.794 15.137 14.185 12.876 29.084
Pesaran-Taylor reset statistic 0.046 0.912 0.194 0.079 0.330 0.784 0.510
Pesaran-Taylor p-value 0.830 0.340 0.660 0.779 0.566 0.376 0.475
Hansen-Sargan test statistic 0.052 0.028 0.292
Hansen-Sargan p-value 0.820 0.868 0.589
Ramsey reset F statistic 0.538 0.003
Probability > F        0.657 1.000
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.6 Preferred expenditure specifications for 2005/06
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10)
PBC 1 PBC 2 PBC 3 PBC 4 PBC 5 PBC 6 PBC 7 PBC 8 PBC 9 PBC 10
infectious cancer blood endocrine mental health LDisability neurological vision hearing circulatory
2005/6 spend 2005/6 spend 2005/6 spend 2005/6 spend 2005/6 spend 2005/06 spend 2005/06 spend 2005/6 spend 2005/6 spend 2005/6 spend
SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7
spend model spend model spend model spend model spend model spend model spend model spend model spend model spend model
instrument n/a instrument o/need instrument n/a instrument n/a instrument n/a instrument n/a instrument n/a instrument o/need instrument n/a instrument o/need
weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted
OLS IV second stage OLS OLS OLS OLS OLS IV second stage OLS IV second stage
GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 05 actual census 06 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05
VARIABLES 06/07 specification 06/07 revised 06/07 specification 06/07 specification 06/07 specification 6/7 revised 6/7 specification 06/07 specification 06/07 specification 06/07 specification
           
lLAgall_56 1.205*** 1.592*** 1.486*** 0.663*** 0.991*** 0.449* 1.220*** 1.127*** 0.762** 1.477***













lSYLLRallcause567 -0.978** -0.364*** -0.061 -0.890*** -0.189
[0.393] [0.134] [0.195] [0.263] [0.286]
LLONEPARH05 0.727***
[0.198]



































































Constant -3.136*** -0.270 0.095 -0.417 -1.681 0.915 -0.722 1.527 -3.186* 1.952*
[1.008] [1.991] [2.383] [0.844] [1.496] [1.474] [1.304] [0.987] [1.801] [1.147]
Observations 149 151 151 151 151 137 151 151 151 151
R-squared 0.780 0.282 0.382 0.690 0.058 0.312 0.240
Ramsey reset F statistic 2.114 0.768 0.813 0.895 1.344 1.913 1.140
Probability > F 0.101 0.514 0.489 0.445 0.263 0.130 0.335
Endogeneity test statistic 8.069 4.617 21.249
Endogeneity p-value 0.005 0.032 0.000
Kleibergen-Paap LM test statistic 14.048 38.585 25.420
Kleibergen-Paap p-value 0.000 0.000 0.000
Kleibergen-Paap F statistic 15.505 48.814 22.302
Pesaran-Taylor reset statistic 0.048 0.008 0.084
Pesaran-Taylor p-value 0.826 0.928 0.772
Hansen-Sargan test statistic 0.117 0.060
Hansen-Sargan p-value        0.733  0.806
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.6 continued  Preferred expenditure specifications for 2005/06
 (1) (2) (3) (4) (5) (6) (7) (8)
PBC 11 PBC 13 PBC 14 PBC 15 PBC 16 PBC 17 PBC 1819 PBC 20
respiratory gastro skin problems musculo-skeletal trauma genito- mat/neonates poisoning
2005/6 spend 2005/6 spend 2005/06 spend 2005/06 spend 2005/6 spend 2005/6 spend 2005/06 spend 2005/6 spend
SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 infant mort rate 2005/06/07 SYLLR 2005/6/7
spend model spend model spend model spend model spend model spend model spend model spend model
instrument o/need instrument o/need instrument n/a instrument n/a instrument n/a instrument n/a o/need exogenous instrument o/need
weighted weighted weighted weighted weighted weighted weighted weighted
IV second stage IV second stage OLS OLS OLS OLS OLS IV second stage
GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05
VARIABLES 06/07 revised 06/07 specification 06/07 revised 06/07 specification 06/07 revised 06/07 specification 06/07 specification 06/07 specification
         
lSYLLRacExResp567 -0.381*
[0.207]
lLAgall_56 1.225*** 1.076*** 0.840*** 0.935*** 0.897*** 1.079*** 0.865*** 1.735***
[0.191] [0.154] [0.190] [0.205] [0.250] [0.264] [0.157] [0.264]
LNQUAL17405 0.414*** 0.416*** 0.175** 0.449***
[0.075] [0.059] [0.079] [0.136]
lSYLLRacExGast567 -0.413**
[0.199]
lSYLLRallcause567 0.033 0.038 -0.170 -0.127 -1.235***













Constant -1.704** -0.274 -2.722*** -4.523*** -0.836 -0.755 -1.145 -1.676
[0.779] [0.721] [0.924] [1.593] [2.201] [2.014] [0.869] [1.299]
Observations 151 151 151 151 151 151 151 151
Endogeneity test statistic 4.593 1.596 15.227
Endogeneity p-value 0.032 0.206 0.000
Kleibergen-Paap LM test statistic 27.275 34.219 33.883
Kleibergen-Paap p-value 0.000 0.000 0.000
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Kleibergen-Paap F statistic 57.822 107.256 40.297
Pesaran-Taylor reset statistic 0.002 1.800 0.260
Pesaran-Taylor p-value 0.964 0.180 0.610
Hansen-Sargan test statistic 1.785
Hansen-Sargan p-value 0.182
R-squared 0.412 0.395 0.464 0.441 0.497
Ramsey reset F statistic 1.493 2.060 1.611 1.397 0.840
Probability > F   0.219 0.108 0.190 0.246 0.474  
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.6 continued  Preferred expenditure specifications for 2005/06
 (1) (2) (3)
PBC 21 PBC 22 PBC 23a
HI social care GMS
2005/6 spend 2005/6 spend 2005/6 spend
SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7
spend model spend model spend model
instrument o/need instrument o/need instrument n/a
weighted weighted weighted
IV second stage IV second stage OLS
GMM2S GMM2S
LA-level LA-level LA-level
actual mortality actual mortality actual mortality
actual census 05 actual census 05 actual census 05
VARIABLES re-derived 06/07 specification 06/07 specification
    
lSYLLRallcause567 0.413 -0.893* -0.102*
[0.342] [0.532] [0.052]










Constant -5.832*** 1.173 1.929***
[2.224] [2.588] [0.347]
Observations 151 116 147
R-squared 0.391
Endogeneity test statistic 0.304 0.599
Endogeneity p-value 0.581 0.439
Hansen-Sargan test statistic 1.658 3.943
Hansen-Sargan p-value 0.646 0.268
Kleibergen-Paap LM test statistic 36.779 33.298
Kleibergen-Paap p-value 0.000 0.000
Kleibergen-Paap F statistic 50.792 38.220
Pesaran-Taylor reset statistic 0.527 0.000
Pesaran-Taylor p-value 0.468 0.984
Ramsey reset F statistic 0.691
Probability > F   0.559
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.7 Preferred outcome specifications for 2006/07
 (1) (2) (3) (4) (5) (6) (7) (8) (9)
PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13 PBC 17 PBC 1819
infectious cancer endocrine neurological circulatory respiratory gastro genito-urinary mat/neonates
2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend
SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 mortality rate 2006/7/8
outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model
instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend instrument n/a instrument spend
weighted weighted weighted weighted weighted weighted weighted weighted weighted
IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage OLS IV second stage
GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 actual census 06
VARIABLES 07/08 revised 07/08 revised 07/08 revised+ re-derived++ 07/08 specification 07/08 specification 07/08 specification
re-derived 
5%/95% OLS re-derived+







lLAimd_2007exexpobook 0.519*** 0.765*** 0.307*** 0.292
[0.113] [0.178] [0.082] [0.191]
lLAg2_67 -0.239***
[0.083]
lLAneedCARAN67 0.914*** 2.296*** 2.781** 4.015*** 0.917**
























































































Constant 2.248** 6.052*** 8.080* 7.442*** 10.621*** 18.286*** 8.505*** -2.020 2.104
[0.944] [0.364] [4.157] [2.483] [1.006] [5.109] [2.703] [2.908] [1.481]
Observations 148 150 136 117 150 150 149 135 149
Endogeneity test statistic 1.915 8.416 2.828 2.516 35.080 24.628 6.928 0.824
Endogeneity p-value 0.166 0.004 0.093 0.113 0.000 0.000 0.008 0.364
Kleibergen-Paap LM test statistic 9.043 19.866 7.931 16.288 35.077 6.770 10.318 14.757
Kleibergen-Paap p-value 0.003 0.000 0.005 0.001 0.000 0.009 0.001 0.001
Kleibergen-Paap F statistic 15.331 16.380 9.502 7.767 30.494 12.140 15.426 9.216
Pesaran-Taylor reset statistic 0.248 0.358 0.044 0.615 0.039 1.756 0.054 1.239
Pesaran-Taylor p-value 0.618 0.550 0.834 0.433 0.843 0.185 0.817 0.266
Hansen-Sargan test statistic 1.457 0.005 0.624 2.628
Hansen-Sargan p-value 0.227 0.998 0.430 0.105
R-squared 0.222
Ramsey reset F statistic 0.752
Probability > F        0.523  
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.8 Preferred expenditure specifications for 2006/07
 (1) (2) (3) (4) (5) (6) (7) (8) (9)
PBC 1 PBC 2 PBC 3 PBC 4 PBC 5 PBC 6 PBC 7 PBC 8 PBC 9
infectious cancer blood endocrine mental health LDisability neurological vision hearing
2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/07 spend 2006/07 spend 2006/7 spend 2006/7 spend
SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8
spend model spend model spend model spend model spend model spend model spend model spend model spend model
instrument n/a instrument o/need instrument n/a instrument n/a instrument n/a instrument n/a instrument n/a instrument o/need instrument n/a
weighted weighted weighted weighted weighted weighted weighted weighted weighted
OLS IV second stage OLS OLS OLS OLS OLS IV second stage OLS
GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 actual census 06
VARIABLES 07/08 spec revised 07/08 specification 07/08 specification 07/08 revised 07/08 specification re-derived OLS 7/8 revised OLS 07/08 specification 07/08 revised
          
lLAgall_67 1.051*** 1.219*** 1.037*** 0.630*** 1.143*** 0.410 0.382* 0.931*** 0.989**







LPROFOCCU06 0.647* -0.527*** -0.762*** -0.607**
[0.346] [0.102] [0.243] [0.254]




lSYLLRallcause678 -0.648** -0.397*** -0.561* -0.664** -0.079

































































CONFIDENTIAL - NOT FOR DISTRIBUTION
37
[0.159]
Constant -3.116 -0.773 0.769 -1.014 -2.637 4.214* 2.561* 1.677 -5.653**
[2.237] [1.188] [2.461] [1.017] [1.850] [2.513] [1.334] [1.537] [2.581]
Observations 148 150 150 150 150 150 150 150 150
R-squared 0.698 0.162 0.371 0.739 0.111 0.283 0.253
Ramsey reset F statistic 1.801 0.305 0.553 1.380 0.238 0.219 0.601
Probability > F 0.150 0.822 0.647 0.252 0.870 0.883 0.615
Endogeneity test statistic 12.742 1.869
Endogeneity p-value 0.000 0.172
Hansen-Sargan test statistic 0.194 0.037
Hansen-Sargan p-value 0.660 0.848
Kleibergen-Paap LM test statistic 33.956 34.857
Kleibergen-Paap p-value 0.000 0.000
Kleibergen-Paap F statistic 46.177 74.593
Pesaran-Taylor reset statistic 0.014 0.007
Pesaran-Taylor p-value  0.906      0.931  
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.8 continued  Preferred expenditure specifications for 2006/07
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10)
PBC 10 PBC 11 PBC 12 PBC 13 PBC 14 PBC 15 PBC 16 PBC 17 PBC 1819 PBC 20
circulatory respiratory dental gastro skin problems musculo-skeletal trauma genito- mat/neonates poisoning
2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/07 spend 2006/7 spend
SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 infant mort rate 2006/07/08 SYLLR 2006/7/8
spend model spend model spend model spend model spend model spend model spend model spend model spend model spend model
instrument o/need instrument o/need instrument n/a instrument o/need instrument n/a instrument n/a instrument n/a instrument n/a spend exogenous instrument spend
weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted
IV second stage IV second stage OLS IV second stage OLS OLS OLS OLS OLS IV second stage
GMM2S GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality real mortality
actual census 06 actual census 06 actual census 07 actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 actual census 06
VARIABLES 07/08 specification 07/08 specification re-derived OLS 07/08 revised 07/08 revised 07/08 specification 07/08 specification 07/08 revised 07/08 specification 07/08 revised
           
lLAgall_67 1.578*** 1.287*** 0.835** 1.014*** 0.701*** 0.628** 0.705*** 0.988*** 0.614** 1.107***
[0.270] [0.221] [0.392] [0.210] [0.249] [0.246] [0.233] [0.242] [0.245] [0.300]
lSYLLRallcause678 0.628 -0.124 0.341 0.273 0.167 -0.667***











LNQUAL17406 0.553*** 0.273*** 0.402*** 0.133















Constant 1.221 -3.159*** -9.116 -0.291 -1.325 -5.128*** -2.329** -0.867 -1.203 -1.069
[1.349] [1.195] [5.559] [1.014] [1.338] [1.863] [1.041] [1.298] [1.307] [1.571]
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Observations 150 150 150 150 150 150 150 150 150 150
Endogeneity test statistic 26.058 7.261 4.381 11.024
Endogeneity p-value 0.000 0.007 0.036 0.001
Hansen-Sargan test statistic 0.158 0.478 1.866
Hansen-Sargan p-value 0.691 0.489 0.172
Kleibergen-Paap LM test statistic 27.832 34.096 29.551 35.141
Kleibergen-Paap p-value 0.000 0.000 0.000 0.000
Kleibergen-Paap F statistic 33.179 56.202 85.706 59.640
Pesaran-Taylor reset statistic 0.140 0.314 0.004 0.024
Pesaran-Taylor p-value 0.708 0.575 0.949 0.876
R-squared 0.343 0.286 0.277 0.230 0.358 0.391
Ramsey reset F statistic 2.275 1.670 0.503 0.759 1.568 1.269
Probability > F   0.083  0.176 0.681 0.519 0.200 0.287  
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.8 continued  Preferred expenditure specifications for 2006/07
 (1) (2) (3)
PBC 21 PBC 22 PBC 23a
HI social care GMS
2006/7 spend 2006/07 spend 2006/7 spend
SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8
spend model spend model spend model




actual mortality actual mortality actual mortality
actual census 07 actual census 06 actual census 06
VARIABLES re-derived 07/08 specification OLS 07/08 specification
    
lLAgall_67 0.709 1.702*** 0.447***
[0.432] [0.489] [0.112]












Constant -4.143 -3.938* 1.621***
[3.699] [2.367] [0.452]
Observations 150 103 145
R-squared 0.134 0.102 0.367
Ramsey reset F statistic 1.695 0.312 0.757
Probability > F 0.171 0.817 0.520
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.9 Preferred outcome specifications for 2007/08
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10)
PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13 PBC 16 PBC 17 PBC 1819
infectious cancer endocrine Neurological circulatory respiratory gastro trauma genito-urinary mat/neonates
2007/8 spend 2007/8 spend 2007/8 spend 2007/08 spend 2007/8 spend 2008/9 spend 2007/8 spend 2007/8 spend 2007/8 spend 2007/08 spend
SYLLR 2007/8/9 SYLLR 2007/8/9 SYLLR 2007/8/9 SYLLR 2007/08/09 SYLLR 2007/8/9 SYLLR 2008/9/10 SYLLR 2007/8/9 SMR 2007/8/9 SMR 2007/8/9 infant mort rate 2007/08/09
outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model
instrument spend instrument spend instrument spend instrument n/a instrument spend instrument spend instrument spend instrument spend instrument spend spend exogenous
weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted
IV second stage IV second stage IV second stage OLS IV second stage IV second stage IV second stage IV second stage IV second stage OLS
GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 07 actual census 07 actual census 07 actual census 07 actual census 07 actual census 07 actual census 07 actual census 07 actual census 07 actual census 07
VARIABLES 08/09 revised 08/09 specification 08/09 revised re-derived, OLS 08/09 revised 08/09 revised 08/09 specification re-derived re-derived 08/09 specification+











lLAneedCARAN78 0.958*** 2.168*** 1.838*** 3.565*** 3.822*** 3.887** 1.494***
[0.092] [0.266] [0.699] [0.574] [0.984] [1.700] [0.292]
lLAg4_78 -1.491
[1.274]















































































Constant 2.369*** 6.221*** 4.252 2.837*** 10.071*** 16.150*** 6.713*** 0.585 8.451 3.206***
[0.697] [0.380] [3.874] [0.998] [0.837] [3.573] [1.824] [1.158] [7.152] [0.601]
Observations 148 152 133 150 152 152 151 151 152 151
R-squared 0.182 0.404
Endogeneity test statistic 3.991 12.271 1.372 37.856 18.331 6.454 1.100 1.226
Endogeneity p-value 0.046 0.000 0.241 0.000 0.000 0.011 0.294 0.268
Hansen-Sargan test statistic 0.898 0.726 0.013 0.604 0.100
Hansen-Sargan p-value 0.343 0.394 0.908 0.437 0.751
Kleibergen-Paap LM test statistic 19.326 20.419 8.726 31.136 9.921 12.416 11.511 10.176
Kleibergen-Paap p-value 0.000 0.000 0.003 0.000 0.002 0.000 0.003 0.006
Kleibergen-Paap F statistic 9.757 19.300 9.375 43.326 20.194 18.138 8.192 6.291
Pesaran-Taylor reset statistic 1.118 1.587 0.184 1.828 1.547 0.018 0.049 0.910
Pesaran-Taylor p-value 0.290 0.208 0.668 0.176 0.214 0.892 0.825 0.340
Ramsey reset F statistic 1.220 0.766
Probability > F    0.305      0.515
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.10 Preferred expenditure specifications for 2007/08
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11)
PBC 1 PBC 2 PBC 3 PBC 4 PBC 5 PBC 6 PBC 7 PBC 8 PBC 9 PBC 10 PBC 11
infectious cancer blood endocrine mental health LDisability neurological vision hearing circulatory respiratory
2007/8 spend 2007/8 spend 2007/8 spend 2007/8 spend 2007/8 spend 2007/08 spend 2007/8 spend 2007/8 spend 2007/8 spend 2007/8 spend 2008/9 spend
SYLLR 2007/8/9 SYLLR 2007/8/9 SYLLR 2007/8/9 SYLLR 2007/8/9 SYLLR 2007/8/9 SYLLR 2007/08/09 SYLLR 2008/9/10 SYLLR 2007/8/9 SYLLR 2007/8/9 SYLLR 2007/8/9 SYLLR 2008/9/10
spend model spend model spend model spend model spend model spend model spend model spend model spend model spend model spend model
instrument n/a
instrument 









weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted
OLS IV second stage OLS OLS OLS OLS IV second stage IV second stage OLS IV second stage IV second stage
GMM2S GMM2S GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 07 actual census 07 actual census 07 actual census 07 actual census 07 actual census 07 actual census 07 actual census 07
actual census 











specification 08/09 revised re-derived+ 08/09 revised
08/09 
specification 08/09 revised
            
lLAgall_78 1.387*** 1.626*** 1.374*** 0.455*** 1.103*** 0.386 0.733*** 1.106*** 0.951* 1.614*** 1.555***









LPROFOCCU07 -0.596*** -0.785*** -0.661***
[0.120] [0.270] [0.253]
lSYLLRallcause789 -0.612** -0.397*** -0.715*** -0.647*** 0.029
[0.294] [0.108] [0.259] [0.222] [0.457]
LLONEPARH07 0.600***
[0.162]
LNQUAL17407 0.721 0.545*** 0.721*** 0.382***










































































Constant -3.903*** -1.505 -1.767 1.812 -2.007* 4.456* 4.038* 0.021 -5.920* 2.204 -2.864**
[1.044] [1.535] [2.716] [1.118] [1.202] [2.439] [2.136] [1.235] [3.073] [1.357] [1.307]
Observations 150 152 152 152 152 152 152 152 152 152 152
R-squared 0.731 0.248 0.504 0.788 0.163 0.267
Ramsey reset F statistic 0.873 0.552 1.644 0.056 0.901 2.082
Probability > F 0.457 0.648 0.182 0.982 0.442 0.105
Endogeneity test statistic 18.550 4.929 6.902 24.020 15.379
Endogeneity p-value 0.000 0.026 0.009 0.000 0.000
Hansen-Sargan test statistic 2.043 1.683 0.296 1.130 0.220
Hansen-Sargan p-value 0.153 0.195 0.587 0.288 0.639
Kleibergen-Paap LM test 
statistic 32.362 22.137 34.077 27.389 34.114
Kleibergen-Paap p-value 0.000 0.000 0.000 0.000 0.000
Kleibergen-Paap F statistic 49.406 35.000 87.353 29.951 54.028
Pesaran-Taylor reset statistic 0.590 0.342 1.152 0.002 1.060
Pesaran-Taylor p-value  0.442     0.559 0.283  0.967 0.303
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.10 continued  Preferred expenditure specifications for 2007/08
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11)
PBC 12 PBC 13 PBC 14 PBC 15 PBC 16 PBC 17 PBC 1819 PBC 20 PBC 21 PBC 22 PBC 23a
dental gastro skin problems musculo-skeletal trauma genito- mat/neonates poisoning HI social care GMS









infant mort rate 
2007/08/09 SYLLR 2007/8/9
SYLLR 
2007/08/09 SYLLR 2007/8/9 SYLLR 2007/8/9
spend model spend model spend model spend model spend model spend model spend model spend model spend model spend model spend model
instrument n/a
instrument 







weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted
OLS IV second stage OLS OLS OLS OLS OLS IV second stage OLS IV second stage OLS
GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual 
mortality actual mortality actual mortality actual mortality actual mortality
actual 
mortality actual mortality real mortality actual mortality real mortality actual mortality
actual census 
07 actual census 07 actual census 07 actual census 07 actual census 07
actual census 
07 actual census 07 actual census 07 actual census 07 actual census 07 actual census 07






specification 08/09 revised 08/09 specification OLS 08/09 revised re-derived, OLS+ re-derived+
08/09 
specification
            
lLAgall_78 0.420*** 1.490*** 0.787*** 0.733*** 1.328*** 1.015*** 0.563** 1.674*** 1.296** 1.669** 0.553***
[0.150] [0.296] [0.203] [0.198] [0.293] [0.218] [0.242] [0.382] [0.544] [0.804] [0.110]
LLONEPARH07 0.179**
[0.079]
LNQUAL17407 0.094 0.390*** 0.057 0.476*** 0.033
[0.078] [0.098] [0.178] [0.142] [0.266]
lSYLLRallcause789 0.215 -0.062 0.278 0.041 0.230 -1.095*** -0.078 -0.423 -0.062
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[0.468]
Constant 0.328 -1.286 -3.063** -2.570 -5.264*** -2.654*** -1.238 -2.162 -7.075* -6.170** 1.347***
[1.039] [1.375] [1.174] [1.597] [1.084] [0.916] [1.382] [1.918] [3.584] [2.758] [0.453]
Observations 135 152 152 152 152 152 152 152 152 110 151
R-squared 0.485 0.389 0.455 0.418 0.362 0.406 0.121 0.324
Ramsey reset F statistic 1.996 1.692 1.341 1.301 1.846 0.849 0.333 1.210
Probability > F 0.118 0.171 0.264 0.277 0.141 0.469 0.801 0.308
Endogeneity test statistic 6.175 12.926 2.286
Endogeneity p-value 0.013 0.000 0.131
Hansen-Sargan test statistic 2.634 1.952 0.598
Hansen-Sargan p-value 0.105 0.162 0.897
Kleibergen-Paap LM test 
statistic 34.752 34.935 25.636
Kleibergen-Paap p-value 0.000 0.000 0.000
Kleibergen-Paap F statistic 50.766 54.957 14.920
Pesaran-Taylor reset statistic 0.130 0.012 0.189
Pesaran-Taylor p-value  0.719      0.914  0.664  
Robust standard errors in 
brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.11 Preferred outcome specifications for 2008/09
 (1) (2) (3) (4) (5) (6) (7) (8) (9)
PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13 PBC 17 PBC 1819
infectious cancer endocrine neurological circulatory respiratory gastro genito-urinary mat/neonates
2008/9 spend 2009/10 spend 2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend 2008/09 spend
SYLLR 2008/9/10 SYLLR 2009/10/11 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 infant mort rate 2008/09/10
outcome model outcome model outcome model outcome model outcome model outcome model outcome model spend model outcome model
instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend instrument n/a spend exogenous
weighted weighted weighted weighted weighted weighted weighted weighted weighted
IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage OLS OLS
GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 08 actual census08 actual census 08 actual census 08 actual census 08 actual census 08 actual census 08 actual census 08 actual census 08
VARIABLES 09/10 revised 09/10 specification 09/10 specification PCT specification 09/10 specification 09/10 specification 09/10 revised PCT specification 09/10 specification+











lLAneedCARAN 0.953*** 1.254 2.924*** 1.913* 3.774*** 1.630***
















































































Constant 1.873*** 6.277*** 4.188* 2.757 11.178*** 18.058*** 8.100*** 3.126 2.582***
[0.488] [0.349] [2.205] [2.697] [1.018] [3.907] [1.957] [2.877] [0.633]
Observations 148 152 149 148 152 151 150 143 151
R-squared 0.134 0.442
Endogeneity test statistic 3.777 10.300 4.581 0.931 25.219 15.773 11.326
Endogeneity p-value 0.052 0.001 0.032 0.334 0.000 0.000 0.001
Hansen-Sargan test statistic 2.602 0.523 3.587 0.566 2.626
Hansen-Sargan p-value 0.272 0.470 0.166 0.452 0.105
Kleibergen-Paap LM test statistic 22.335 25.882 9.327 16.084 24.567 11.562 13.871
Kleibergen-Paap p-value 0.000 0.000 0.002 0.001 0.000 0.003 0.000
Kleibergen-Paap F statistic 10.459 32.476 10.515 10.630 43.471 14.269 28.799
Pesaran-Taylor reset statistic 0.028 0.123 0.911 1.459 0.017 0.154 0.627
Pesaran-Taylor p-value 0.867 0.726 0.340 0.227 0.897 0.695 0.429
Ramsey reset F statistic 0.731 0.339
Probability > F        0.535 0.797
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.12 Preferred expenditure specifications for 2008/09
 (1) (2) (3) (4) (5) (6) (7) (8)
PBC 1 PBC 2 PBC 3 PBC 4 PBC 5 PBC 7 PBC 8
infectious cancer blood endocrine mental health PBC 6 neurological vision
2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend LDisability 2008/9 spend 2008/9 spend
SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 2008/09 spend SYLLR 2008/9/10 SYLLR 2008/9/10
spend model spend model spend model spend model spend model SYLLR 2008/09/10 spend model spend model
instrument n/a instrument o/need instrument n/a instrument n/a instrument n/a spend model instrument o/need instrument o/need
weighted weighted weighted weighted weighted instrument n/a weighted weighted
OLS IV second stage OLS OLS OLS weighted IV second stage IV second stage
GMM2S OLS GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 08 actual census 08 actual census 08 actual census 08 actual census 08 actual census 08 actual census 08 actual census 08
VARIABLES 09/10 specification 09/10 specification 09/10 specification 09/10 revised OLS 09/10 specification 09/10 specification 09/10 specification 09/10 specification
         
lLAgall_89 1.471*** 0.784** 0.995*** 0.498*** 0.995*** 0.329 0.897*** 0.701***













lSYLLRallcause890 -0.672** -0.303*** -0.460* -0.544**








































































Constant -5.190*** 5.048* 1.139 0.073 -1.644 3.663* -1.466 2.541**
[1.130] [2.695] [1.594] [0.976] [1.724] [2.101] [0.992] [1.057]
Observations 150 152 152 150 152 152 150 152
R-squared 0.783 0.194 0.579 0.789 0.104
Ramsey reset F statistic 1.513 1.512 1.186 0.465 1.764
Probability > F 0.214 0.214 0.317 0.707 0.157
Endogeneity test statistic 19.732 8.533 4.237
Endogeneity p-value 0.000 0.003 0.040
Hansen-Sargan test statistic 1.028 0.081 0.592
Hansen-Sargan p-value 0.311 0.776 0.442
Kleibergen-Paap LM test statistic 36.285 32.990 34.619
Kleibergen-Paap p-value 0.000 0.000 0.000
Kleibergen-Paap F statistic 56.425 82.270 51.873
Pesaran-Taylor reset statistic 0.002 0.809 0.143
Pesaran-Taylor p-value  0.968     0.368 0.705
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.12 continued  Preferred expenditure specifications for 2008/09
 (1) (2) (3) (4) (5) (6) (7) (8)
PBC 9 PBC 10 PBC 11 PBC 12 PBC 13 PBC 14 PBC 15 PBC 16
hearing circulatory respiratory dental gastro skin problems musculo-skeletal trauma
2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend 2008/09 spend 2008/09 spend 2008/9 spend
SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/09/11 SYLLR 2008/09/10 SYLLR 2008/9/10
spend model spend model spend model spend model spend model spend model spend model spend model
instrument n/a instrument o/need instrument o/need instrument n/a instrument o/need instrument n/a instrument n/a instrument n/a
weighted weighted weighted weighted weighted weighted weighted weighted
OLS IV second stage IV second stage OLS IV second stage OLS OLS OLS
GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 08 actual census 08 actual census 08 actual census 08 actual census 08 actual census 08 actual census 08 actual census 08
VARIABLES 09/10 specification 09/10 spec revised 09/10 specification rederived OLS 09/10 specification 09/10 specification re-derived+ OLS 09/10 specification
         
lLAgall_89 1.637*** 1.784*** 0.752** 0.428** 0.520* 0.907*** 0.738*** 1.344***
[0.369] [0.276] [0.352] [0.198] [0.278] [0.199] [0.195] [0.222]
LOWNOCC08 0.377 0.278**
[0.255] [0.110]
lSYLLRallcause890 0.143 0.279 0.001 -0.271

























Constant -10.672*** -0.118 5.422* -1.183 8.403*** -4.278*** -2.206 -3.653***
[1.776] [1.402] [2.892] [1.513] [2.751] [1.256] [1.617] [0.989]
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Observations 152 152 152 152 152 152 152 152
R-squared 0.256 0.501 0.495 0.541 0.348
Ramsey reset F statistic 0.130 3.756 1.203 1.296 0.793
Probability > F 0.942 0.012 0.311 0.278 0.500
Endogeneity test statistic 31.218 17.243 14.052
Endogeneity p-value 0.000 0.000 0.000
Hansen-Sargan test statistic 0.278 0.097 0.009
Hansen-Sargan p-value 0.598 0.756 0.924
Kleibergen-Paap LM test statistic 28.178 34.175 32.639
Kleibergen-Paap p-value 0.000 0.000 0.000
Kleibergen-Paap F statistic 29.651 34.268 22.222
Pesaran-Taylor reset statistic 0.232 0.092 0.391
Pesaran-Taylor p-value  0.630 0.761  0.532    
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.12 continued  Preferred expenditure specifications for 2008/09
 (1) (2) (3) (4) (5) (6)
PBC 17 PBC 1819 PBC 20 PBC 21 PBC 22 PBC 23a
genito- maternity poisoning HI social care GMS
2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend
SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10
spend model spend model spend model spend model spend model spend model
instrument n/a instrument o/need instrument o/need instrument n/a instrument n/a instrument n/a
weighted weighted weighted weighted weighted weighted
OLS IV second stage IV second stage OLS OLS OLS
GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality real mortality actual mortality actual mortality actual mortality
actual census 08 actual census 08 actual census 08 actual census 08
VARIABLES 09/10 specification 09/10 specification 09/10 specification 09/10 specification 09/10 specification 09/10 specification





lLAneedCARAN 0.251 2.102*** 1.049
[0.299] [0.546] [0.809]
lLAgall_89 0.733*** 0.963*** 0.674* 0.952 1.192* 0.338***
[0.213] [0.339] [0.366] [0.699] [0.605] [0.089]
lSYLLRallcause890 -0.299 -1.433*** 0.076 -0.463 -0.028
[0.341] [0.356] [0.326] [0.410] [0.071]
lLAmatneedindexpp 0.809***
[0.135]
Constant -0.747 -0.903 6.637* -3.945 -2.416 2.672***
[1.897] [0.819] [3.581] [5.837] [3.223] [0.350]
Observations 152 152 152 152 106 150
R-squared 0.491 0.368 0.049 0.228
Ramsey reset F statistic 1.741 0.317 0.331 0.753
Probability > F 0.161 0.813 0.803 0.522
Endogeneity test statistic 1.649 19.393
Endogeneity p-value 0.199 0.000
Hansen-Sargan test statistic 2.648 0.006
Hansen-Sargan p-value 0.266 0.936
Kleibergen-Paap LM test statistic 15.039 33.275
Kleibergen-Paap p-value 0.002 0.000
Kleibergen-Paap F statistic 11.224 33.862
Pesaran-Taylor reset statistic 0.215 0.029
Pesaran-Taylor p-value  0.643 0.865    
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.13 Preferred outcome specifications for 2009/10
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10)
PBC 1 PBC 2 PBC 04 PBC 07 PBC 10 PBC 11 PBC 13 PBC 17 PBC 1819 PBC 16
infectious 
diseases cancer endocrine etc neurological circulatory respiratory gastro-intestinal genito-urinary mat/neonates trauma/injuries
















outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model
instrument spend instrument spend instrument spend instrument spend
instrument 
spend instrument spend instrument spend instrument spend o/need exogenous spend exogenous
weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted
IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage OLS OLS
GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 09 actual census09 actual census 09 actual census 09 actual census 09 actual census 09 actual census 09 actual census 09 actual census 09 actual census 09
VARIABLES Re-derived 08/09 version
08/09 revised 
v2(SI) Re-derived(SI)+ 08/09 version Re-derived 08/09 revised(SI) Re-derived Re-derived, OLS Re-derived, OLS











lLACARANneed910 0.881*** 1.191 3.041*** 1.433** 4.291*** 2.019*** 1.163***




























































































Constant 1.418*** 6.559*** 2.834** 14.608*** 13.415*** 21.341*** 11.868** 20.235** 2.152*** -0.876
[0.505] [0.594] [1.404] [5.131] [1.873] [6.014] [4.923] [9.485] [0.462] [0.585]
Observations 147 150 148 140 150 148 148 150 149 143
R-squared 0.413 0.141
Endogeneity test statistic 1.862 5.166 6.368 3.034 34.858 13.820 8.584 2.256
Endogeneity p-value 0.172 0.023 0.012 0.082 0.000 0.000 0.003 0.133
Hansen-Sargan test statistic 5.056 0.020 0.877 0.766 2.729
Hansen-Sargan p-value 0.168 0.888 0.349 0.381 0.099
Kleibergen-Paap LM test 
statistic 25.041 23.944 13.637 7.203 14.621 11.432 6.617 26.731
Kleibergen-Paap p-value 0.000 0.000 0.000 0.007 0.001 0.003 0.010 0.000
Kleibergen-Paap F statistic 8.698 17.787 17.223 10.204 10.903 9.051 8.446 19.945
Pesaran-Taylor reset statistic 1.073 0.329 2.068 0.575 0.000 1.083 0.251 1.449
Pesaran-Taylor p-value 0.300 0.566 0.150 0.448 0.995 0.298 0.616 0.229
Ramsey reset F statistic 1.439 0.050
Probability > F         0.234 0.985
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.14 Preferred expenditure specifications for 2009/10
 (1) (2) (3) (4) (5) (6) (7) (8) (9)
PBC 1 PBC 2 PBC 4 PBC 7
infectious cancer PBC 3 diabetes PBC 5 PBC 6 epilepsy PBC 8 PBC 9
2009/10 spend 2009/10 spend Blood disorders 2009/10 spend Mental health LDisability 2009/10 spend Vision hearing problems
SYLLR 2009/10/11 SYLLR 2009/10/11 2009/10 spend all causeSYLLR 2009/10/11 2009/10 spend 2009/10 spend all causeSYLLR 2009/10/11 2009/10 spend 2009/10 spend
spend model spend model SYLLR 2009/10/11 spend model SYLLR 2009/10/11 SYLLR 2009/10/11 spend model SYLLR 2009/10/11 SYLLR 2009/10/11
instrument n/a instrument other needs spend model instrument o/need spend model spend model instrument o/need spend model spend model
weighted weighted instrument n/a weighted instrument n/a instrument n/a weighted instrument o/need instrument n/a
OLS IV second stage weighted IV second stage weighted weighted IV second stage weighted weighted
GMM2S OLS GMM2S OLS OLS GMM2S GMM2S OLS
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 09 actual census09 actual census 09 actual census 09 actual census 09 actual census 09 actual census 09 actual census 09 actual census 09
VARIABLES 08/09 version revised(XR) Re-derived, OLS 08/09 version 08/09 version Re-derived, OLS 08/09 version 08/09 revised Re-derived, OLS
          
lLAgall_0910 0.968*** 0.502** 1.060*** 0.708*** 0.899*** 0.647** 0.850*** 0.934*** 1.273***













lSYLLRallcause901 -0.850*** -0.107 -0.577** -0.482* 0.310









































































Constant -2.991** 6.566*** 2.197 0.164 -1.794 2.204 0.406 0.262 -8.969***
[1.338] [1.661] [1.634] [1.976] [2.060] [1.477] [0.977] [0.967] [1.774]
Observations 147 150 150 148 150 150 140 150 150
R-squared 0.752 0.270 0.765 0.139 0.256
Ramsey reset F statistic 0.970 0.592 0.345 1.023 0.479
Probability > F 0.409 0.621 0.793 0.385 0.698
Endogeneity test statistic 17.406 1.531 2.882 3.238
Endogeneity p-value 0.000 0.216 0.090 0.072
Hansen-Sargan test statistic 1.235 0.171 0.785 0.736
Hansen-Sargan p-value 0.267 0.679 0.376 0.391
Kleibergen-Paap LM test statistic 25.606 27.318 30.560 23.051
Kleibergen-Paap p-value 0.000 0.000 0.000 0.000
Kleibergen-Paap F statistic 27.743 23.097 55.103 17.739
Pesaran-Taylor reset statistic 0.042 0.832 0.073 0.028
Pesaran-Taylor p-value  0.838  0.362   0.787 0.866  
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.14 continued  Preferred expenditure specifications for 2009/10
 (1) (2) (3) (4) (5) (6) (7) (8) (9)
PBC 10 PBC 11 PBC 13 PBC 17 PBC 1819
circulatory respiratory PBC 12 gastro PBC 14 PBC 15 PBC 16 renal maternity/neonates
2009/10 spend 2009/10 spend dental problems 2009/10 spend skin problems musculo-skeletal trauma/injuries 2009/10 spend 2009/10 spend
SYLLR 2009/10/11 SYLLR 2009/10/11 2009/10 spend SYLLR 2009/10/11 2009/10 spend 2009/10 spend 2009/10 spend SYLLR 2009/10/11 all causeSYLLR 2009/10/11
spend model spend model SYLLR 2009/10/11 spend model SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 spend model spend model
instrument o/need instrument other needs spend model instrument other needs spend model spend model spend model instrument n/a instrument o/need
weighted weighted instrument n/a weighted instrument n/a instrument n/a instrument n/a weighted weighted
IV second stage IV second stage weighted IV second stage weighted weighted weighted OLS IV second stage
GMM2S GMM2S OLS GMM2S OLS OLS OLS GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census09 actual census09 actual census 09 actual census09 actual census 09 actual census 09 actual census 09 actual census 09 actual census 09
VARIABLES 08/09 version 08/09 version Re-derived, OLS 08/09 version Re-derived, OLS Re-derived, OLS 08/09 version 08/09 version 08/09 version
          
lSYLLRacExResp901 -0.565**
[0.273]
lLAgall_0910 0.494* 0.576*** 0.765*** 0.387* 0.890*** 0.295 1.090*** 0.878*** 0.653***
[0.267] [0.218] [0.188] [0.231] [0.192] [0.263] [0.215] [0.207] [0.233]
lLACARANneed910 2.458*** 1.252*** 1.292*** 0.965*** 0.218





lSYLLRallcause901 0.167 -0.046 0.180 -0.219 -0.405*



















Constant 12.640*** 3.491 -2.268** 5.218** -3.817** 0.574 -2.171* -0.939 2.072***
[3.154] [2.136] [0.977] [2.254] [1.517] [2.551] [1.157] [1.794] [0.704]
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Observations 150 148 150 148 148 150 150 150 150
Endogeneity test statistic 23.688 7.777 9.122 1.253
Endogeneity p-value 0.000 0.005 0.003 0.263
Hansen-Sargan test statistic 0.267 0.024 0.389 0.212
Hansen-Sargan p-value 0.606 0.877 0.533 0.899
Kleibergen-Paap LM test statistic 16.668 26.156 32.784 35.340
Kleibergen-Paap p-value 0.000 0.000 0.000 0.000
Kleibergen-Paap F statistic 11.755 22.221 29.989 69.224
Pesaran-Taylor reset statistic 0.022 0.171 2.482 0.050
Pesaran-Taylor p-value 0.883 0.679 0.115 0.822
R-squared 0.482 0.496 0.564 0.236 0.487
Ramsey reset F statistic 1.405 1.358 1.392 0.948 1.995
Probability > F   0.244  0.258 0.248 0.419 0.117  
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.14 continued  Preferred expenditure specifications for 2009/10
 (1) (2) (3) (4)
PBC 20 PBC 21 PBC 22 PBC 23a
poisoning HI social care GMS
2009/10 spend 2009/10 spend 2009/10 spend 2009/10 spend
SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11
spend model spend model spend model spend model
instrument o/need instrument n/a instrument n/a instrument n/a
weighted weighted weighted weighted
GMM2S OLS OLS OLS
LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality
actual census 09 actual census 09 actual census 09 actual census 09
VARIABLES 08/09 version 08/09 version Re-derived, OLS Re-derived, OLS
     
lSYLLRallcause901 -0.816*** 0.232 -0.177 0.010
[0.302] [0.323] [0.432] [0.071]
lLAgall_0910 0.658** 1.246** 0.844 0.564***
[0.304] [0.506] [0.563] [0.085]
lLACARANneed910 1.110*** 0.939
[0.390] [0.570]
Constant 3.017 -7.085* -1.640 0.751**
[2.692] [4.068] [2.855] [0.369]
Observations 150 150 97 148
R-squared 0.385 0.035 0.463
Endogeneity test statistic 12.352
Endogeneity p-value 0.000
Hansen-Sargan test statistic 0.078
Hansen-Sargan p-value 0.781
Kleibergen-Paap LM test statistic 25.438
Kleibergen-Paap p-value 0.000
Kleibergen-Paap F statistic 21.297
Pesaran-Taylor reset statistic 0.008
Pesaran-Taylor p-value 0.928
Ramsey reset F statistic 0.507 1.066 0.112
Probability > F  0.678 0.368 0.953
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.15 Preferred outcome specifications for 2010/11
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10)
PBC 1 PBC 2 PBC 04 PBC 07 PBC 10 PBC 11 PBC 13 PBC 17 PBC 1819 PBC 16
infectious 
diseases cancer endocrine etc neurological etc circulatory respiratory gastro-intestinal genito-urinary
maternity/neonate
s trauma/injuries









20010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12
SYLLR 
2010/11/12 SYLLR 2010/11/12 SMR<75 skull fracture
outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model
instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend spend exogenous
weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted
IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage OLS
GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 10 actual census10 actual census 10 actual census 10 actual census 10 actual census 10 actual census 10 actual census 10 actual census 10 actual census 10





09/10 version & Re-derived, 
OLS









lLACARANneed1011 0.841*** 0.994** 2.170*** 3.324*** 2.165*** 1.003***
























































































Constant 0.927 6.119*** 0.468 2.968 12.742*** 26.332*** 9.358*** 9.693 1.389 0.618
[0.638] [0.369] [0.611] [2.232] [1.931] [7.442] [2.781] [11.907] [1.212] [0.548]
Observations 147 150 149 150 150 150 150 152 149 134
R-squared 0.157
Endogeneity test statistic 0.845 6.251 1.359 28.477 21.491 13.803 1.615 0.121
Endogeneity p-value 0.358 0.012 0.244 0.000 0.000 0.000 0.204 0.728
Hansen-Sargan test statistic 0.162 0.882 1.843
Hansen-Sargan p-value 0.688 0.348 0.175
Kleibergen-Paap LM test statistic 13.677 27.563 11.334 16.195 8.269 6.906 10.628 18.511
Kleibergen-Paap p-value 0.001 0.000 0.001 0.000 0.004 0.009 0.001 0.000
Kleibergen-Paap F statistic 9.561 25.020 16.653 12.595 10.897 8.704 11.406 23.729
Pesaran-Taylor reset statistic 2.067 0.468 0.312 0.117 0.000 0.128 1.600 0.129
Pesaran-Taylor p-value 0.150 0.494 0.576 0.732 0.994 0.721 0.206 0.719
Ramsey reset F statistic 0.324 0.049
Probability > F   0.808       0.985
Robust standard errors in 
brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.16 Preferred expenditure specifications for 2010/11
 (1) (2) (3) (4) (5) (6) (7) (8) (9)
PBC 1 PBC 2 PBC 4 PBC 7
infectious cancer PBC 3 diabetes PBC 5 PBC 6 epilepsy PBC 8 PBC 9
2010/11 spend 2010/11 spend Blood disorders 2010/11 spend Mental health LDisability 2010/11 spend Vision hearing problems
SYLLR 2010/11/12 SYLLR 2010/11/12 2010/11 spend SYLLR 2010/11/12 2009/10 spend 2010/11 spend all cause SYLLR 2010/11/12 2010/11 spend 2010/11 spend
spend model spend model SYLLR 2010/11/12 spend model SYLLR 2009/10/11 SYLLR 2010/11/12 spend model SYLLR 2010/11/12 SYLLR 2010/11/12
instrument n/a instrument other needs spend model instrument o/need spend model spend model instrument o/need spend model spend model
weighted weighted instrument n/a weighted instrument n/a instrument o/need weighted instrument o/need instrument n/a
OLS IV second stage weighted IV second stage weighted weighted IV second stage weighted weighted
GMM2S OLS GMM2S OLS GMM2S GMM2S GMM2S OLS
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 10 actual census10 actual census 10 actual census 1- actual census 09 actual census 10 actual census 10 actual census 10 actual census 10
VARIABLES 09/10 version 09/10 version Re-derived, OLS Re-derived +XR 09/10 version Re-derived plus Re-derived 09/10 version 09/10 version
          
lLAgall_1011 1.006*** 0.438 0.332 0.696*** 0.973*** 1.208** 0.557*** 0.997*** 0.808*













lSYLLRallcause012 0.286 -0.109 -1.601** -0.593** 0.599














































































Constant -5.084*** 9.093*** -0.747 0.904 -2.280 -1.164 -1.088 0.526 -7.387***
[1.584] [2.751] [1.445] [1.034] [2.392] [3.074] [1.998] [0.928] [2.104]
Observations 148 150 150 150 150 137 150 150 150
R-squared 0.782 0.283 0.606 0.168
Ramsey reset F statistic 1.263 0.226 0.083 0.627
Probability > F 0.290 0.878 0.969 0.599
Endogeneity test statistic 18.766 4.212 3.883 2.038 3.617
Endogeneity p-value 0.000 0.040 0.049 0.153 0.057
Hansen-Sargan test statistic 0.229 2.634 0.044 0.310 0.271
Hansen-Sargan p-value 0.632 0.268 0.833 0.578 0.603
Kleibergen-Paap LM test statistic 23.548 32.240 20.213 24.854 23.506
Kleibergen-Paap p-value 0.000 0.000 0.000 0.000 0.000
Kleibergen-Paap F statistic 30.069 56.655 20.440 22.773 18.701
Pesaran-Taylor reset statistic 0.009 2.378 0.205 0.551 0.051
Pesaran-Taylor p-value  0.923  0.123  0.651 0.458 0.821  
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.16 continued  Preferred expenditure specifications for 2010/11
 (1) (2) (3) (4) (5) (6) (7) (8) (9)
PBC 10 PBC 11 PBC 17 PBC 1819
circulatory respiratory PBC 12 PBC 13 PBC 14 PBC 15 PBC 16 renal maternity/neonates
2010/11 spend 2010/11 spend dental problems gastro problems skin problems musculo-skeletal trauma/injuries 2010/11 spend 2010/11 spend
SYLLR 2010/11/12 SYLLR 2010/11/12 2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend SYLLR 2010/11/12 all causeSYLLR 2010/11/12
spend model spend model SYLLR 2010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12 spend model spend model
instrument o/need instrument o/need spend model spend model spend model spend model spend model instrument n/a instrument o/need
weighted weighted instrument n/a instrument o/need instrument o/need instrument n/a instrument n/a weighted weighted
IV second stage IV second stage weighted weighted weighted weighted weighted OLS IV second stage
GMM2S GMM2S OLS GMM2S GMM2S OLS OLS GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census10 actual census10 actual census 10 actual census 10 actual census 10 actual census 10 actual census 10 actual census 10 actual census 10
VARIABLES Re-derived 09/10 version revised Re-derived, OLS 09/10 revised Re-derived
09/10 version, 
OLS plus 09/10 version revised 09/10 version revised 09/10 version
          
lSYLLRacExCirc012 -0.979***
[0.252]
lLAgall_1011 1.013*** 1.192*** 0.229 1.040*** 0.422* 0.489** 0.589** 0.631*** 0.342
[0.223] [0.268] [0.192] [0.315] [0.235] [0.226] [0.250] [0.135] [0.233]
LNQUAL17410 0.458*** 0.345*** 0.339*** 0.412***
[0.090] [0.094] [0.118] [0.130]
lSYLLRacExResp012 -0.547*
[0.320]
lSYLLRallcause012 -0.023 -0.285 0.341 -0.032 -0.253























Constant 3.705*** -0.718 2.190 1.298 3.586 -1.983 0.523 -0.928 3.394***
[0.979] [1.102] [1.812] [1.395] [2.551] [1.812] [1.605] [0.577] [0.909]
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Observations 150 150 150 150 147 150 150 150 150
Endogeneity test statistic 14.309 8.904 5.635 2.987 0.593
Endogeneity p-value 0.000 0.003 0.018 0.084 0.441
Hansen-Sargan test statistic 0.689 0.101 3.182 3.084
Hansen-Sargan p-value 0.406 0.751 0.204 0.214
Kleibergen-Paap LM test statistic 20.987 22.353 26.652 25.360 32.544
Kleibergen-Paap p-value 0.000 0.000 0.000 0.000 0.000
Kleibergen-Paap F statistic 20.267 17.314 73.904 23.609 75.024
Pesaran-Taylor reset statistic 2.257 1.617 0.342 0.087 0.876
Pesaran-Taylor p-value 0.133 0.204 0.559 0.769 0.349
R-squared 0.431 0.417 0.181 0.388
Ramsey reset F statistic 2.118 1.833 1.758 0.307
Probability > F   0.101   0.144 0.158 0.821  
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.16 continued  Preferred expenditure specifications for 2010/11
 (1) (2) (3) (4)
PBC 20 PBC 21 PBC 22 PBC 23a
poisoning HI social care GMS
2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend
SYLLR 2010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12
spend model spend model spend model spend model
instrument o/need instrument n/a instrument n/a instrument n/a
weighted weighted weighted weighted
GMM2S OLS OLS OLS
LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality
actual census 10 actual census 10 actual census 10 actual census 10
VARIABLES 09/10 version revised 09/10 version revised 09/10 version 09/10 version
     
lSYLLRallcause012 -1.109** 0.258 -0.260 0.050
[0.500] [0.461] [0.539] [0.104]
lLAgall_1011 1.078** 1.359** 1.592** 0.520***
[0.457] [0.594] [0.673] [0.120]
LNQUAL17410 0.420*** 0.413
[0.156] [0.336]
Constant 2.149 -7.612* -6.686** 0.790
[1.650] [4.097] [2.913] [0.585]
Observations 150 149 93 150
R-squared 0.200 0.119 0.365
Endogeneity test statistic 6.385
Endogeneity p-value 0.012
Hansen-Sargan test statistic 1.613
Hansen-Sargan p-value 0.204
Kleibergen-Paap LM test statistic 23.506
Kleibergen-Paap p-value 0.000
Kleibergen-Paap F statistic 18.701
Pesaran-Taylor reset statistic 0.128
Pesaran-Taylor p-value 0.720
Ramsey reset F statistic 1.080 0.437 1.133
Probability > F  0.360 0.727 0.338
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.17 Preferred outcome specifications for 2011/12
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10)
PBC 1 PBC 2 PBC 04 PBC 07 PBC 10 PBC 11 PBC 13 PBC 17 PBC 1819 PBC 16
infectious cancer endocrine etc neurological etc circulatory respiratory gastro-intestinal renal mat/neonates trauma/injuries


















2011/12/13 SMR<75 skull fracture
spend model outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model
instrument n/a instrument spend instrument n/a instrument spend instrument spend instrument spend instrument spend instrument n/a spend exogenous spend exogenous
weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted
OLS IV second stage OLS IV second stage IV second stage IV second stage IV second stage OLS OLS OLS
GMM2S GMM2S GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 11 actual census11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11
VARIABLES Re-derived, OLS 10/11 version SI 10/11 version Re-derived+ 10/11 version 10/11 version 10/11 version DI Re-derived, OLS 10/11 version
10/11 version & Re-derived, 
OLS











lLACARANneed1112 1.055*** 2.452*** 4.078*** 1.989*** 1.266***


























































































Constant -0.523 7.072*** 0.581 12.713 12.292*** 23.178*** 11.964*** 2.395 1.830*** -0.140
[0.454] [0.727] [0.735] [8.281] [1.675] [5.233] [4.389] [3.962] [0.579] [0.773]
Observations 145 148 147 148 148 148 148 148 147 149
R-squared 0.629 0.329 0.113 0.245 0.196
Ramsey reset F statistic 0.313 0.806 0.273 0.835 0.443
Probability > F 0.816 0.492 0.845 0.477 0.723
Endogeneity test statistic 9.404 2.857 25.774 14.703 10.016
Endogeneity p-value 0.002 0.091 0.000 0.000 0.002
Kleibergen-Paap LM test statistic 11.267 8.458 17.541 15.098 7.239
Kleibergen-Paap p-value 0.001 0.004 0.000 0.000 0.007
Kleibergen-Paap F statistic 14.773 8.746 17.472 18.118 9.678
Pesaran-Taylor reset statistic 1.934 0.015 0.009 2.624 0.177
Pesaran-Taylor p-value 0.380 0.902 0.925 0.105 0.674
Hansen-Sargan test statistic 2.060
Hansen-Sargan p-value     0.151      
Robust standard errors in 
brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.18 Preferred expenditure specifications for 2011/12
 (1) (2) (3) (4) (5) (6) (7) (8) (9)
PBC 1 PBC 2 PBC 3 PBC 4 PBC 5 PBC 6 PBC 7 PBC 8 PBC 9
infectious cancer Blood disorders diabetes Mental health LDisability epilepsy Vision hearing problems
2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend
SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13
spend model spend model spend model spend model spend model spend model spend model spend model spend model
instrument n/a instrument other needs instrument n/a instrument o/need instrument n/a instrument n/a instrument o/need instrument o/need instrument n/a
weighted weighted weighted weighted weighted weighted weighted weighted weighted
OLS IV second stage OLS IV second stage OLS OLS IV second stage IV second stage OLS
GMM2S GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 11 actual census11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11
VARIABLES 10/11 version 10/11 version 10/11 version 10/11 revised 10/11 version Re-derived, OLS 10/11 revised 10/11 version Re-derived,OLS2
          
lLAgall_1112 0.841*** 0.961** 0.876*** 1.116*** 1.194*** 0.741* 0.703*** 1.279*** 1.231***











LPROFOCCU11 -0.394*** -0.691*** -0.280
[0.146] [0.251] [0.281]
lSYLLRallcause123 0.060 -0.078 -0.042 -1.090*** 0.376








































































Constant -3.654*** 4.919* -3.419*** -1.452* -4.244** -5.250 2.711** 1.685* -9.391***
[1.391] [2.611] [1.204] [0.825] [1.920] [3.403] [1.098] [0.920] [2.474]
Observations 146 148 148 148 148 137 148 148 148
R-squared 0.773 0.367 0.732 0.128 0.306
Ramsey reset F statistic 1.018 0.705 0.108 0.371 0.594
Probability > F 0.387 0.551 0.955 0.774 0.620
Endogeneity test statistic 18.153 11.094 8.472 9.649
Endogeneity p-value 0.000 0.001 0.004 0.002
Hansen-Sargan test statistic 0.103 2.194 1.223 0.023
Hansen-Sargan p-value 0.748 0.334 0.269 0.879
Kleibergen-Paap LM test statistic 19.717 34.180 33.862 22.743
Kleibergen-Paap p-value 0.000 0.000 0.000 0.000
Kleibergen-Paap F statistic 18.612 66.387 117.471 19.191
Pesaran-Taylor reset statistic 0.337 2.356 0.250 0.028
Pesaran-Taylor p-value  0.562  0.125   0.617 0.866  
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.18 continued  Preferred expenditure specifications for 2011/12
 (1) (2) (3) (4) (5) (6) (7) (8) (9)
PBC 10 PBC 11 PBC 12 PBC 13 PBC 14 PBC 15 PBC 16 PBC 17 PBC 1819
circulatory respiratory dental problems gastro problems skin problems musculo-skeletal trauma/injuries renal maternity/neonates
2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend
SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13
spend model spend model spend model spend model spend model spend model spend model spend model spend model
instrument o/need instrument o/need instrument o/need instrument o/need instrument o/need instrument n/a instrument n/a instrument n/a instrument n/a
weighted weighted weighted weighted weighted weighted weighted weighted weighted
IV second stage IV second stage IV second stage IV second stage IV second stage OLS OLS OLS OLS
GMM2S GMM2S GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11
VARIABLES 10/11 version 10/11 revised Re-derived+ 10/11 version+ 10/11 version+ 10/11 version+ 10/11 version+ 10/11 version 10/11 version OLS
          
lSYLLRacExResp123 -0.722***
[0.213]
lLAgall_1112 1.491*** 1.360*** 0.843*** 1.033*** 0.681*** 0.456** 1.024*** 0.598*** 0.481***
[0.234] [0.177] [0.181] [0.210] [0.225] [0.222] [0.193] [0.124] [0.180]
LNQUAL17411 0.414*** 0.392*** 0.361*** 0.151
[0.083] [0.074] [0.065] [0.106]




lSYLLRallcause123 0.107 -0.259 0.215 -0.154 -0.217
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Constant 1.354 -0.873 -2.750* 0.802 1.193 -1.132 -2.656** -0.550 2.147**
[1.022] [0.777] [1.531] [0.834] [1.652] [1.368] [1.111] [0.563] [0.858]
Observations 148 148 148 148 145 148 148 148 148
R-squared 0.499 0.242 0.434 0.601
Endogeneity test statistic 22.129 15.086 1.201 6.134 1.993
Endogeneity p-value 0.000 0.000 0.273 0.013 0.158
Hansen-Sargan test statistic 0.892 0.027 1.361 1.197
Hansen-Sargan p-value 0.345 0.870 0.243 0.274
Kleibergen-Paap LM test statistic 20.617 22.588 24.305 29.448 25.703
Kleibergen-Paap p-value 0.000 0.000 0.000 0.000 0.000
Kleibergen-Paap F statistic 19.918 19.840 51.658 94.008 35.963
Pesaran-Taylor reset statistic 0.545 0.836 2.153 0.127 0.000
Pesaran-Taylor p-value 0.460 0.360 0.142 0.722 0.992
Ramsey reset F statistic 1.326 0.561 0.514 1.711
Probability > F      0.268 0.642 0.673 0.168
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.18 continued  Preferred expenditure specifications for 2011/12
 (1) (2) (3) (4)
PBC 20 PBC 21 PBC 22 PBC 23a
poisoning HI social care GMS
2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend
SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13
spend model spend model spend model spend model
instrument o/need instrument n/a instrument n/a instrument n/a
weighted weighted weighted weighted
IV second stage OLS OLS OLS
GMM2S
LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality
actual census 11 actual census 11 actual census 11 actual census 11
VARIABLES 10/11 version 10/11 version 10/11 version 10/11 version +
     
lSYLLRallcause123 -0.206 0.570 -0.698* -0.096
[0.286] [0.388] [0.400] [0.103]
lLAgall_1112 0.631** 1.748*** 1.859*** 0.518***





Constant -0.147 -12.970*** -5.898** 1.496**
[1.023] [3.136] [2.922] [0.719]
Observations 148 147 102 148
R-squared 0.319 0.121 0.430
Endogeneity test statistic 1.908
Endogeneity p-value 0.167
Hansen-Sargan test statistic 0.020
Hansen-Sargan p-value 0.887
Kleibergen-Paap LM test statistic 22.743
Kleibergen-Paap p-value 0.000
Kleibergen-Paap F statistic 19.191
Pesaran-Taylor reset statistic 0.753
Pesaran-Taylor p-value 0.385
Ramsey reset F statistic 0.458 0.864 1.273
Probability > F  0.712 0.462 0.286
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.19 Preferred outcome specifications for 2012/13
 (1) (2) (3) (4) (5) (6) (7) (8) (9)
PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13 PBC 17 PBC 1819
infectious cancer endocrine etc neurological etc circulatory respiratory gastro-intestinal renal mat/neonates
2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend
SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 infant m/rate 2012/13/14
spend model outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model
instrument n/a instrument spend instrument spend instrument n/a instrument spend instrument spend instrument spend instrument n/a spend exogenous
weighted weighted weighted weighted weighted weighted weighted weighted weighted
OLS IV second stage IV second stage OLS IV second stage IV second stage IV second stage OLS OLS
GMM2S GMM2S GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 11 actual census11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11
VARIABLES 11/12 version 11/12 version Re-derived Re-derived, OLS 11/12 version 11/12 revised 11/12 revised Re-derived+ 11/12 version











lLACARANneed1213 1.023*** 2.304*** 3.878*** 2.141* 1.926***


















































































Constant 0.698 6.744*** 1.118 -0.032 11.541*** 23.203*** 11.547*** 9.081* 1.529**
[0.437] [0.691] [1.164] [0.782] [1.302] [3.903] [4.024] [4.938] [0.671]
Observations 147 149 149 149 149 149 149 149 148
R-squared 0.582 0.107 0.233 0.229
Ramsey reset F statistic 1.139 1.414 2.110 1.064
Probability > F 0.336 0.241 0.102 0.366
Endogeneity test statistic 8.481 0.064 30.621 20.193 8.574
Endogeneity p-value 0.004 0.801 0.000 0.000 0.003
Kleibergen-Paap LM test statistic 10.435 27.631 24.067 19.742 10.507
Kleibergen-Paap p-value 0.001 0.000 0.000 0.000 0.001
Kleibergen-Paap F statistic 11.262 24.515 19.517 16.644 10.363
Pesaran-Taylor reset statistic 0.408 1.563 0.086 0.096 0.039
Pesaran-Taylor p-value 0.523 0.211 0.769 0.757 0.843
Hansen-Sargan test statistic 1.428 0.810 2.227
Hansen-Sargan p-value   0.490  0.368 0.136    
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.20 Preferred expenditure specifications for 2012/13
 (1) (2) (3) (4) (5) (6) (7) (8) (9)
PBC 1 PBC 2 PBC 3 PBC 4 PBC 5 PBC 6 PBC 7 PBC 8 PBC 9
infectious cancer blood disorders diabetes mental health LDisability epilepsy vision hearing issues
2011/12 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend
SYLLR 2011/12/13 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 all cause SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14
spend model spend model spend model spend model spend model spend model spend model spend model spend model
instrument n/a instrument o/ need instrument n/a instrum o/need instrument n/a instrument n/a instrum o/need instrum o/need instrument n/a
weighted weighted weighted weighted weighted weighted weighted weighted weighted
OLS IV second stage OLS IV second stage OLS OLS IV second stage IV second stage OLS
GMM2S GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 11 actual census11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11
VARIABLES 11/12 revised 11/12 version 11/12 version 11/12 revised 11/12 version Re-derived, OLS 11/12 version 11/12 version 11/12 version
          
lLAgall_1213 0.749*** 1.027** 1.119*** 0.951*** 1.023*** 0.000 0.856*** 1.411*** 1.523***















lSYLLRallcause234 -0.321* 0.043 0.245 -1.047*** 0.419




































































Constant -3.303** 5.169 -2.932** 0.056 -3.512* 1.414 2.362** 0.395 -11.656***
[1.322] [3.768] [1.213] [0.737] [1.994] [2.473] [1.205] [0.930] [2.388]
Observations 147 149 149 149 149 135 149 149 149
R-squared 0.788 0.301 0.715 0.081 0.329
Ramsey reset F statistic 2.104 0.196 1.023 0.388 1.093
Probability > F 0.103 0.899 0.384 0.762 0.354
Endogeneity test statistic 28.098 8.114 13.076 9.351
Endogeneity p-value 0.000 0.004 0.000 0.002
Hansen-Sargan test statistic 0.008 2.726 0.918 1.707
Hansen-Sargan p-value 0.929 0.099 0.338 0.191
Kleibergen-Paap LM test statistic 18.904 28.095 33.802 24.062
Kleibergen-Paap p-value 0.000 0.000 0.000 0.000
Kleibergen-Paap F statistic 18.752 43.928 130.353 23.271
Pesaran-Taylor reset statistic 2.365 1.162 0.643 0.736
Pesaran-Taylor p-value  0.124  0.281   0.422 0.391  
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.20 continued  Preferred expenditure specifications for 2012/13
 (1) (2) (3) (4) (5) (6) (7) (8) (9)
PBC 10 PBC 11 PBC 12 PBC 13 PBC 14 PBC 15 PBC 16 PBC 17 PBC 1819
circulatory respiratory dental problems gastro problems skin problems musculo-skeletal trauma/injuries renal maternity/neonates
2012/13 spend 2011/12 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend
SYLLR 2012/13/14 SYLLR 2011/12/13 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14
spend model spend model spend model spend model spend model spend model spend model spend model spend model
instrument o/need instrument o/need instrument o/need instrument o/need instrument o/need instrument n/a instrument n/a instrument n/a instrument n/a
weighted weighted weighted weighted weighted weighted weighted weighted weighted
IV second stage IV second stage IV second stage IV second stage IV second stage OLS OLS OLS OLS
GMM2S GMM2S GMM2S GMM2S GMM2S
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality
actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11
VARIABLES 11/12 revised 11/12 version Re-derived 11/12 version 11/12 revised 11/12 version 11/12 version 11/12 version 11/12 version
          
lSYLLRacExCirc234 -0.908***
[0.159]
lLAgall_1213 1.285*** 0.928*** 0.855*** 0.997*** 1.158*** 0.725*** 1.058*** 0.855*** 0.833***
[0.161] [0.163] [0.158] [0.171] [0.322] [0.184] [0.171] [0.119] [0.159]
LNQUAL17411 0.382*** 0.408*** 0.357*** 0.173*
[0.078] [0.071] [0.076] [0.094]






lSYLLRallcause234 -0.276* -0.976* 0.210 -0.270** -0.472***








































































Constant 1.110 0.296 0.237 0.942 1.704 -3.635** -2.230** -1.375** 1.035
[0.993] [0.744] [1.060] [0.872] [2.538] [1.403] [0.961] [0.623] [0.783]
Observations 149 149 149 149 147 149 149 149 149
R-squared 0.594 0.240 0.505 0.676
Endogeneity test statistic 12.964 6.507 2.711 7.495 4.994
Endogeneity p-value 0.000 0.011 0.100 0.006 0.025
Hansen-Sargan test statistic 2.162 0.000 2.463
Hansen-Sargan p-value 0.141 0.985 0.482
Kleibergen-Paap LM test statistic 31.331 23.711 43.690 29.937 15.054
Kleibergen-Paap p-value 0.000 0.000 0.000 0.000 0.000
Kleibergen-Paap F statistic 65.251 23.538 50.773 122.358 20.121
Pesaran-Taylor reset statistic 0.807 0.484 0.354 0.023 0.002
Pesaran-Taylor p-value 0.369 0.487 0.552 0.878 0.964
Ramsey reset F statistic 0.257 1.071 0.879 0.323
Probability > F      0.856 0.363 0.454 0.809
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.20 continued  Preferred expenditure specifications for 2012/13
 (1) (2) (3) (4)
PBC 20 PBC 21 PBC 22 PBC 23a
poisoning HI social care GMS
2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend
SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14
spend model spend model spend model spend model
instrument o/need instrument n/a instrument n/a instrument n/a
weighted weighted weighted weighted
IV second stage OLS OLS OLS
GMM2S
LA-level LA-level LA-level LA-level
actual mortality actual mortality actual mortality actual mortality
actual census 11 actual census 11 actual census 11 actual census 11
VARIABLES 11/12 version 11/12 revised 11/12 revised 11/12 version
     
lSYLLRallcause234 -0.601*** -0.455 -0.852** -0.113
[0.229] [0.488] [0.408] [0.088]
lLAgall_1213 1.124*** 1.172* 1.613*** 0.585***







Constant -1.673 1.059 -3.927 1.115*
[1.280] [5.485] [2.680] [0.654]
Observations 149 149 133 149
R-squared 0.234 0.210 0.474
Endogeneity test statistic 8.286
Endogeneity p-value 0.004
Hansen-Sargan test statistic 0.008
Hansen-Sargan p-value 0.930
Kleibergen-Paap LM test statistic 24.062
Kleibergen-Paap p-value 0.000
Kleibergen-Paap F statistic 23.271
Pesaran-Taylor reset statistic 1.578
Pesaran-Taylor p-value 0.209
Ramsey reset F statistic 0.056 2.080 1.333
Probability > F  0.983 0.106 0.266
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1































































A2.3 First stage of IV regressions results tables
Table A2.21 First stage of IV regressions, preferred outcome specifications for 2003/04
Table A2.22 First stage of IV regressions, preferred expenditure specifications for 2003/04
Table A2.23 First stage of IV regressions, preferred outcome specifications for 2004/05
Table A2.24 First stage of IV regressions, preferred expenditure specifications for 2004/05
Table A2.25 First stage of IV regressions, preferred outcome specifications for 2005/06
Table A2.26 First stage of IV regressions, preferred expenditure specifications for 2005/06
Table A2.27 First stage of IV regressions, preferred outcome specifications for 2006/07
Table A2.28 First stage of IV regressions, preferred expenditure specifications for 2006/07
Table A2.29 First stage of IV regressions, preferred outcome specifications for 2007/08
Table A2.30 First stage of IV regressions, preferred expenditure specifications for 2007/08
Table A2.31 First stage of IV regressions, preferred outcome specifications for 2008/09
Table A2.32 First stage of IV regressions, preferred expenditure specifications for 2008/09
Table A2.33 First stage of IV regressions, preferred outcome specifications for 2009/10
Table A2.34 First stage of IV regressions, preferred expenditure specifications for 2009/10
Table A2.35 First stage of IV regressions, preferred outcome specifications for 2010/11
Table A2.36 First stage of IV regressions, preferred expenditure specifications for 2010/11
Table A2.37 First stage of IV regressions, preferred outcome specifications for 2011/12
Table A2.38 First stage of IV regressions, preferred expenditure specifications for 2011/12
Table A2.39 First stage of IV regressions, preferred outcome specifications for 2012/13
Table A2.40 First stage of IV regressions, preferred expenditure specifications for 2012/13
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Table A2.21 First stage of IV regressions, preferred outcome specifications for 2003/04
(1) (2) (3) (4) (5) (6) (7)
PBC 1 PBC 2 PBC 7 PBC 10 PBC 11 PBC 13 PBC 17
Infectious Cancer Neurological Circulatory Respiratory Gastro-intestinal Genito-urinary





SYLLR 2003/04/05 SYLLR 
2003/04/05
SYLLR 2003/04/05 SYLLR 2003/04/05 SYLLR 2003/04/05
























lLAneedCARAN34 0.396** -0.077 1.185*** -0.640** 1.402***













Constant 1.321 5.263*** 2.509*** 6.727*** 4.034*** 6.516*** 3.816***
[1.156] [0.274] [0.685] [0.267] [0.015] [0.302] [0.225]
Observations 144 151 135 151 151 151 151
K-P F statistic 9.795 10.26 10.04 55.86 28.45 24.26 24.69
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.22 First stage of IV regressions, preferred expenditure specifications for 2003/04
(1) (2) (3) (4) (5) (6) (7) (8)
PBC 2 PBC 8 PBC 9 PBC 10 PBC 11 PBC 13 PBC 20 PBC 21
Cancer Vision Hearing Circulatory Respiratory Gastro-intestinal Poisoning Healthy 
individuals




































LNQUAL17403 0.169*** 0.224*** 0.487*** 0.558*** 0.148*** 0.547*** 0.123***
[0.063] [0.054] [0.050] [0.049] [0.046] [0.049] [0.044]
lLAgall_34netpoppheadOHP 0.875*** 0.366*** 0.162* 0.631*** 0.624*** 0.109 0.711*** 0.176**
[0.099] [0.119] [0.092] [0.085] [0.082] [0.090] [0.085] [0.081]
LLONEPENH03 -0.578*** -0.400*** -0.034 -0.142* -0.248***
[0.086] [0.061] [0.063] [0.082] [0.080]
LPOPPUCAR03 -0.414*** -0.347*** -0.559*** -0.388***













Constant -2.154*** 3.812*** 5.587*** 1.059* 1.195** 4.757*** 0.534 6.022***
[0.643] [0.909] [0.627] [0.569] [0.546] [0.589] [0.556] [0.548]
Observations 151 151 151 151 151 151 151 151
K-P F statistic 45.58 35.89 28.34 19.12 48.93 96.40 35.17 19.39
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.23 First stage of IV regressions, preferred outcome specifications for 2004/05
(1) (2) (3) (4) (5) (6)
PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13
Cancer Endocrine Neurological Circulatory Respiratory Gastro-intestinal
2004/05 spend 2004/05 spend 2004/05 spend 2004/05 spend 2004/05 spend 2004/05 spend
SYLLR 2004/05/06 SYLLR 2004/05/06 SYLLR 2004/05/06 SYLLR 2004/05/06 SYLLR 2004/05/06 SYLLR 2004/05/06
Outcome Outcome Outcome Outcome Outcome Outcome













lLAneedCARAN45 0.522*** 0.426** 1.226*** 0.807***









Constant 5.183*** 2.332*** 2.240*** 6.187*** 4.160*** 5.213***
[0.260] [0.437] [0.648] [0.225] [0.013] [0.160]
Observations 151 136 137 151 151 151
K-P F statistic 9.441 10.81 14.11 67.07 13.55 33.42
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.24 First stage of IV regressions, preferred expenditure specifications for 2004/05
(1) (2) (3) (4) (5) (6) (7)
PBC 2 PBC 8 PBC 9 PBC 10 PBC 11 PBC 13 PBC 20
Cancer Vision Hearing Circulatory Respiratory Gastro-intestinal Poisoning
































LNQUAL17404 0.139** 0.227*** 0.493*** 0.561*** 0.146*** 0.552***
[0.064] [0.059] [0.053] [0.053] [0.046] [0.052]
lLAgall_45netpoppheadOHP 0.567*** 0.225* 0.127 0.626*** 0.624*** 0.035 0.692***
[0.138] [0.120] [0.098] [0.083] [0.081] [0.093] [0.081]
LLONEPENH04 -0.411*** -0.403*** -0.046 -0.137 -0.251***
[0.108] [0.061] [0.065] [0.089] [0.085]
LPOPPUCAR04 -0.409*** -0.390*** -0.594*** -0.416***











Constant 0.061 4.860*** 5.679*** 0.920 1.026* 5.175*** 0.490
[1.035] [0.959] [0.786] [0.591] [0.582] [0.628] [0.568]
Observations 151 151 151 151 151 151 151
K-P F statistic 14.61 41.91 40.25 23.03 58.44 112.8 40.54
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.25 First stage of IV regressions, preferred outcome specifications for 2005/06
(1) (2) (3) (4) (5) (6) (7)
PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13
Infectious Cancer Endocrine Neurological Circulatory Respiratory Gastro-intestinal
2005/06 spend 2005/06 spend 2005/06 spend 2005/06 spend 2005/06 spend 2005/06 spend 2005/06 spend
SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07
Outcome Outcome Outcome Outcome Outcome Outcome Outcome







lLAimd_2007exexpobook 0.524*** 0.243*** 0.151
[0.095] [0.043] [0.111]




lLAneedCARAN56 0.754*** 0.344 1.254*** 0.934***



















Constant 2.294*** 5.294*** 3.176*** 6.006 6.120*** 4.259*** 5.233***
[0.143] [0.262] [0.426] [4.475] [0.312] [0.017] [0.158]
Observations 149 151 136 136 151 151 151
K-P F statistic 19.09 15.86 9.794 15.14 14.19 12.88 29.08
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.26 First stage of IV regressions, preferred expenditure specifications for 2005/06
(1) (2) (3) (4) (5) (6) (7) (8)
PBC 2 PBC 8 PBC 10 PBC 11 PBC 13 PBC 20 PBC 21 PBC 22
Cancer Vision Circulatory Respiratory Gastro-intestinal Poisoning Healthy individuals Social care
2005/06 spend 2005/06 spend 2005/06 spend 2005/06 spend 2005/06 spend 2005/06 spend 2005/06 spend 2005/06 spend
SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07
Expenditure Expenditure Expenditure Expenditure Expenditure Expenditure Expenditure Expenditure
VARIABLES first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage 
regression
LLONEPENH05 -0.393*** -0.395*** -0.145 -0.245***
[0.100] [0.057] [0.089] [0.088]
lLAgall_56netpoppheadOHP 0.601*** 0.191* 0.607*** 0.604*** 0.062 0.659*** 0.092 0.116







LNQUAL17405 0.140** 0.475*** 0.543*** 0.152*** 0.535*** 0.216*** 0.106
[0.069] [0.055] [0.053] [0.047] [0.053] [0.055] [0.065]
LPOPPUCAR05 -0.389*** -0.616*** -0.431*** -0.300***















Constant -0.169 5.105*** 0.960* 1.031* 4.992*** 0.608 5.810*** 6.691***
[0.952] [0.871] [0.548] [0.530] [0.593] [0.527] [0.677] [0.945]
Observations 151 151 151 151 151 151 151 116
K-P F statistic 15.50 48.81 22.30 57.82 107.3 40.30 50.79 38.22
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.27 First stage of IV regressions, preferred outcome specifications for 2006/07
(1) (2) (3) (4) (5) (6) (7) (8)
PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13 PBC 18 & 19
Infectious Cancer Endocrine Neurological Circulatory Respiratory Gastro-intestinal Maternity
2006/07 spend 2006/07 spend 2006/07 spend 2006/07 spend 2006/07 spend 2006/07 spend 2006/07 spend 2006/07 spend
SYLLR 2006/07/08 SYLLR 2006/07/08 SYLLR 2006/07/08 SYLLR 2006/07/08 SYLLR 2006/07/08 SYLLR 2006/07/08 SYLLR 2006/07/08 SYLLR 2006/07/08
Outcome Outcome Outcome Outcome Outcome Outcome Outcome Outcome
VARIABLES first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression
LPROFOCCU06 0.816*** -0.372*** -0.066 0.242





lLAimd_2007exexpobook 0.586*** -0.176* 0.286*** -0.131 -0.044
[0.118] [0.091] [0.046] [0.132] [0.217]
LLONEPENH06 0.355*** 0.372*** 0.362***
[0.128] [0.097] [0.092]
lLAneedCARAN67 1.355*** 1.190*** 0.977*** 1.093*** 0.938*























Constant 2.122*** 5.634*** 2.798*** 4.276*** 5.249*** 5.078*** 5.018*** 5.073***
[0.200] [0.220] [0.435] [0.913] [0.264] [0.686] [0.188] [1.091]
Observations 148 150 136 117 150 150 149 149
K-P F statistic 15.33 16.38 9.502 7.767 30.49 12.14 15.43 9.216
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.28 First stage of IV regressions, preferred expenditure specifications for 2006/07
(1) (2) (3) (4) (5) (6)
PBC 2 PBC 8 PBC 10 PBC 11 PBC 13 PBC 20
Cancer Vision Circulatory Respiratory Gastro-intestinal Poisoning


























LPOPPUCAR06 -0.292*** -0.402*** -0.429*** -0.452***
[0.102] [0.116] [0.108] [0.113]
LLONEPENH06 -0.433*** -0.441*** -0.210*** -0.283*** -0.300***
[0.089] [0.051] [0.076] [0.071] [0.073]
lLAgall_67netpoppheadOHP 0.888*** 0.327*** 0.721*** 0.729*** 0.148* 0.765***





LNQUAL17406 0.166** 0.413*** 0.449*** 0.156*** 0.467***
[0.064] [0.062] [0.059] [0.053] [0.061]
lLAimd_2007exexpobook 0.263***
[0.028]
Constant -2.896*** 3.930*** -0.127 -0.165 4.395*** -0.438
[0.595] [0.963] [0.605] [0.569] [0.615] [0.588]
Observations 150 150 150 150 150 150
K-P F statistic 46.18 74.59 33.18 56.20 85.71 59.64
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.29 First stage of IV regressions, preferred outcome specifications for 2007/08
(1) (2) (3) (4) (5) (6) (7) (8)
PBC 1 PBC 2 PBC 4 PBC 10 PBC 11 PBC 13 PBC 16 PBC 17
Infectious Cancer Endocrine Circulatory Respiratory Gastro-intestinal Trauma Genito-urinary
2007/08 spend 2007/08 spend 2007/08 spend 2007/08 spend 2007/08 spend 2007/08 spend 2007/08 spend 2007/08 spend
SYLLR 2007/08/09 SYLLR 2007/08/09 SYLLR 2007/08/09 SYLLR 2007/08/09 SYLLR 2007/08/09 SYLLR 2007/08/09 SYLLR 2007/08/09 SYLLR 2007/08/09
Outcome Outcome Outcome Outcome Outcome Outcome Outcome Outcome
VARIABLES first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression
LWHITEEG07 0.322* 0.273***
[0.190] [0.061]
LPROFOCCU07 0.667*** -0.233*** -0.147 0.363***





lLAimd_2007exexpobook 0.539*** 0.024 -0.053
[0.098] [0.097] [0.057]
LLONEPENH07 0.630*** 0.478*** 0.467***
[0.134] [0.097] [0.110]
lLAneedCARAN78 0.670** 1.004*** 0.785*** 1.142*** 1.660*** 1.418***















Constant 2.165*** 5.705*** 4.194*** 5.470*** 6.204*** 5.257*** 3.606*** 5.201***
[0.183] [0.224] [0.392] [0.315] [0.691] [0.222] [0.666] [0.321]
Observations 148 152 133 152 152 151 151 152
K-P F statistic 9.757 19.30 9.375 43.33 20.19 18.14 8.192 6.291
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.30 First stage of IV regressions, preferred expenditure specifications for 2007/08
(1) (2) (3) (4) (5) (6) (7) (8)
PBC 2 PBC 7 PBC 8 PBC 10 PBC 11 PBC 13 PBC 20 PBC 22
Cancer Neurological Vision Circulatory Respiratory Gastro-intestinal Poisoning Social care


































LLONEPENH07 -0.382*** -0.491*** -0.401*** -0.198*** -0.272*** -0.284***
[0.079] [0.064] [0.042] [0.069] [0.064] [0.067]
lLAneedCARAN78 0.737***
[0.206]
lLAgall_78netpoppheadOHP 0.869*** -0.017 0.319** 0.714*** 0.723*** 0.379*** 0.757*** 0.522***
[0.097] [0.120] [0.125] [0.090] [0.087] [0.118] [0.090] [0.150]
lLAepiprev0708 0.216***
[0.067]
LPERMSICK07 0.164*** 0.271*** 0.124**
[0.062] [0.057] [0.057]
LPOPPUCAR07 -0.213* -0.331*** -0.367*** -0.441*** -0.390***
[0.111] [0.122] [0.115] [0.109] [0.119]
LPROFOCCU07 -0.486***
[0.057]
LNQUAL17407 0.176*** 0.387*** 0.423*** 0.366*** 0.440*** 0.076







Constant -2.531*** 6.763*** 4.022*** 0.012 -0.065 2.340*** -0.319 3.427***
[0.614] [0.891] [1.061] [0.629] [0.609] [0.852] [0.629] [1.205]
Observations 152 152 152 152 152 152 152 110
K-P F statistic 49.41 35 87.35 29.95 54.03 50.77 54.96 14.92
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.31 First stage of IV regressions, preferred outcome specifications for 2008/09
(1) (2) (3) (4) (5) (6) (7)
PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13
Infectious Cancer Endocrine Neurological Circulatory Respiratory Gastro-intestinal
2008/09 spend 2008/09 spend 2008/09 spend 2008/09 spend 2008/09 spend 2008/09 spend 2008/09 spend
SYLLR 2008/09/10 SYLLR 2008/09/10 SYLLR 2008/09/10 SYLLR 2008/09/10 SYLLR 2008/09/10 SYLLR 2008/09/10 SYLLR 2008/09/10
Outcome Outcome Outcome Outcome Outcome Outcome Outcome











lLAimd_2007exexpobook 0.472*** 0.004 -0.007
[0.106] [0.076] [0.074]
LLONEPENH08 0.597*** 0.225** 0.389*** 0.423***
[0.112] [0.102] [0.086] [0.079]
lLAneedCARAN 0.801*** 0.559** 1.179*** 0.938*** 1.103***















Constant 3.107*** 5.760*** 4.512*** 4.691*** 5.525*** 6.300*** 5.223***
[0.888] [0.166] [0.572] [0.180] [0.238] [0.690] [0.161]
Observations 148 152 149 148 152 151 150
K-P F statistic 10.46 32.48 10.51 10.63 43.47 14.27 28.80
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.32 First stage of IV regressions, preferred expenditure specifications for 2008/09
(1) (2) (3) (4) (5) (6) (7) (8)
PBC 2 PBC 7 PBC 8 PBC 10 PBC 11 PBC 13 PBC 18 & 19 PBC 20
Cancer Neurological Vision Circulatory Respiratory Gastro-intestinal Maternity Poisoning


































LPOPPUCAR08 -0.296*** -0.365*** -0.319*** -0.149 -0.359*** -0.160
[0.110] [0.116] [0.119] [0.105] [0.091] [0.110]
LLONEPENH08 -0.319*** -0.534*** -0.308*** -0.216*** -0.251*** -0.062 -0.262***
[0.077] [0.058] [0.065] [0.067] [0.074] [0.074] [0.077]
lLAgall_89netpoppheadOHP 0.275* 0.220* 0.784*** 0.745*** -0.005 -0.141 0.439*** 0.013
[0.153] [0.128] [0.082] [0.081] [0.117] [0.112] [0.134] [0.123]
lLAneedCARAN 0.880*** 0.855*** 1.222*** 1.227*** 1.259***















Constant 1.887* 3.412*** -0.588 -0.305 5.193*** 6.085*** 2.109** 5.057***
[1.133] [0.960] [0.589] [0.588] [0.835] [0.800] [0.907] [0.879]
Observations 152 150 152 152 152 152 152 152
K-P F statistic 56.43 82.27 51.87 29.65 34.27 22.22 11.22 33.86
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.33 First stage of IV regressions, preferred outcome specifications for 2009/10
(1) (2) (3) (4) (5) (6) (7) (8)
PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13 PBC 17
Infectious Cancer Endocrine Neurological Circulatory Respiratory Gastro-intestinal Genito-urinary
2009/10 spend 2009/10 spend 2009/10 spend 2009/10 spend 2009/10 spend 2009/10 spend 2009/10 spend 2009/10 spend
SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11
Outcome Outcome Outcome Outcome Outcome Outcome Outcome Outcome













lLAIMD2010 0.564*** -0.042 -0.020
[0.099] [0.057] [0.081]
LLONEPENH09 0.313*** 0.373*** 0.186***
[0.088] [0.118] [0.064]
lLACARANneed910 0.792*** 0.389** 0.851*** 0.306 0.988*** 1.011***





















Constant 3.367*** 5.445*** 5.346*** 6.779*** 5.705*** 7.233*** 4.823*** 4.796***
[0.757] [0.133] [0.599] [0.674] [0.315] [0.677] [0.133] [0.246]
Observations 147 150 148 140 150 148 148 150
K-P F statistic 8.698 17.79 17.22 10.20 10.90 9.051 8.446 19.95
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.34 First stage of IV regressions, preferred expenditure specifications for 2009/10
(1) (2) (3) (4) (5) (6) (7) (8) (9)
PBC 2 PBC 4 PBC 7 PBC 8 PBC 10 PBC 11 PBC 13 PBC 18 & 19 PBC 20
Cancer Endocrine Neurological Vision Circulatory Respiratory Gastro-intestinal Maternity Poisoning







































LLONEPENH09 -0.159* -0.138* -0.498*** -0.190** -0.051 -0.123* -0.078 -0.140*
[0.082] [0.079] [0.059] [0.074] [0.072] [0.068] [0.072] [0.072]
LPOPPUCAR09 -0.402*** -0.315** -0.297** -0.303*** -0.317*** -0.263** -0.314***
[0.123] [0.123] [0.132] [0.109] [0.102] [0.101] [0.105]
lLAgall_0910pheadOHP 0.009 -0.293** 0.219* 0.711*** -0.192* -0.280** -0.338*** 0.130 -0.233**
[0.153] [0.121] [0.125] [0.072] [0.116] [0.117] [0.113] [0.087] [0.112]
lLACARANneed910 1.114*** 1.468*** 0.678*** 1.279*** 1.392*** 1.026*** 1.396***

















Constant 3.944*** 7.081*** 4.927*** 0.213 6.422*** 7.052*** 7.446*** 3.919*** 6.730***
[1.103] [0.811] [0.841] [0.531] [0.789] [0.789] [0.760] [0.632] [0.767]
Observations 150 148 140 150 150 148 148 150 150
K-P F statistic 27.74 23.10 55.10 17.74 11.76 22.22 29.99 69.22 21.30
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.35 First stage of IV regressions, preferred outcome specifications for 2010/11
(1) (2) (3) (4) (5) (6) (7) (8)
PBC 1 PBC 2 PBC 7 PBC 10 PBC 11 PBC 13 PBC 17 PBC 18 & 19
Infectious Cancer Neurological Circulatory Respiratory Gastro-intestinal Genito-urinary Maternity
2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend
SYLLR 2010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12
Outcome Outcome Outcome Outcome Outcome Outcome Outcome Outcome
VARIABLES first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression
LNQUAL17410 -0.506*** 0.209**
[0.151] [0.080]
lLACARANneed1011 1.453*** 0.861*** 0.822*** 0.709*** 1.110*** -0.175





























Constant 2.229*** 5.799*** 4.380*** 5.015*** 8.864*** 3.540*** 4.936*** 4.640***
[0.500] [0.192] [0.019] [0.260] [0.761] [0.298] [0.297] [0.089]
Observations 147 150 150 150 150 150 152 149
K-P F statistic 9.561 25.02 16.65 12.59 10.90 8.704 11.41 23.73
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.36 First stage of IV regressions, preferred expenditure specifications for 2010/11
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11)
PBC 2 PBC 4 PBC 6 PBC 7 PBC 8 PBC 10 PBC 11 PBC 13 PBC 14 PBC 18 & 
19
PBC 20
Cancer Endocrine Learning 
Disability
Neurological Vision Circulatory Respiratory Gastro-intestinal Skin Maternity Poisoning



















































LLONEPENH10 -0.126 -0.265*** -0.290*** -0.255*** -0.165** -0.157** -0.349*** -0.049 -0.165**
[0.083] [0.059] [0.058] [0.064] [0.070] [0.068] [0.059] [0.072] [0.070]
lLAIMD2010 0.240*** 0.227*** 0.265*** 0.132*** 0.251*** 0.345***
[0.038] [0.044] [0.041] [0.037] [0.029] [0.033]
LPROFOCCU10 -0.261*** -0.354*** -0.212*** -0.241** -0.388***
[0.061] [0.071] [0.049] [0.102] [0.048]
lLAgall_1011pheadOHP 0.035 0.301*** -0.020 0.197*** 0.733*** 0.418*** 0.688*** 0.185** 0.673*** 0.124 0.733***
[0.155] [0.091] [0.125] [0.073] [0.069] [0.100] [0.065] [0.078] [0.093] [0.083] [0.069]
LNQUAL17410 -0.643** 0.405*** -0.013 0.390*** 0.140*** 0.405***
[0.270] [0.054] [0.088] [0.052] [0.029] [0.054]
LNQUAL17410SQ -0.169**
[0.083]
LWHITEEG10 0.319*** 0.287*** 0.344*** 0.350***
[0.037] [0.038] [0.062] [0.039]
LPOPPUCAR10 -0.429*** -0.165* -0.345*** -0.315** -0.345***













Constant 3.806*** 1.632** 4.285*** 5.148*** 0.046 2.042** 0.396 4.097*** 0.279 4.091*** 0.046
[1.148] [0.804] [1.008] [0.569] [0.508] [0.791] [0.489] [0.531] [0.922] [0.593] [0.508]
Observations 150 150 137 150 150 150 150 150 147 150 150
K-P F statistic 30.07 56.66 20.44 22.77 18.70 20.27 17.31 73.90 23.61 75.02 18.70
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.37 First stage of IV regressions, preferred outcome specifications for 2011/12
(1) (2) (3) (4) (5)
PBC 2 PBC 7 PBC 10 PBC 11 PBC 13
Cancer Neurological Circulatory Respiratory Gastro-intestinal
2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend
SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13
Outcome Outcome Outcome Outcome Outcome
VARIABLES first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression
lLACARANneed1112 0.716*** 0.647*** 0.600*** 1.082***



















Constant 5.329*** 6.729*** 5.731*** 7.848*** 4.321***
[0.187] [0.461] [0.236] [0.639] [0.049]
Observations 148 148 148 148 148
K-P F statistic 14.77 8.746 17.47 18.12 9.678
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1

















































CONFIDENTIAL - NOT FOR DISTRIBUTION
100
Table A2.38 First stage of IV regressions, preferred expenditure specifications for 2011/12
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10)
PBC 2 PBC 4 PBC 7 PBC 8 PBC 10 PBC 11 PBC 12 PBC 13 PBC 14 PBC 20
Cancer Endocrine Neurological Vision Circulatory Respiratory Dental Gastro-intestinal Skin Poisoning













































LLONEPENH11 -0.086 -0.246*** -0.148* -0.127* -0.244*** -0.385*** -0.148*
[0.094] [0.061] [0.082] [0.075] [0.054] [0.062] [0.082]
lLAIMD2010 0.252*** 0.275*** 0.131*** 0.276*** 0.264***
[0.041] [0.022] [0.042] [0.040] [0.027]
LPROFOCCU11 -0.351*** -0.362*** -0.206* -0.253*** -0.362***
[0.058] [0.063] [0.107] [0.045] [0.043]
lLAgall_1112pheadOHP 0.085 0.180** 0.082 0.719*** 0.400*** 0.655*** 0.115 0.095 0.592*** 0.719***
[0.185] [0.087] [0.077] [0.072] [0.122] [0.066] [0.083] [0.083] [0.076] [0.072]
LNQUAL17411 -0.114 0.420*** 0.044 0.430*** 0.187*** 0.420***
[0.075] [0.055] [0.092] [0.054] [0.032] [0.055]
LWHITEEG11 0.354*** 0.318*** 0.288***
[0.038] [0.032] [0.043]
LPOPPUCAR11 -0.389*** -0.339*** -0.364*** -0.360*** -0.364***









Constant 3.477*** 2.909*** 6.299*** 0.147 2.282** 0.623 3.610*** 4.760*** 0.844 0.147
[1.328] [0.645] [0.594] [0.534] [0.964] [0.480] [0.598] [0.575] [0.786] [0.534]
Observations 148 148 148 148 148 148 148 148 145 148
K-P F statistic 18.61 66.39 117.5 19.19 19.92 19.84 51.66 94.01 35.96 19.19
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.39 First stage of IV regressions, preferred outcome specifications for 2012/13
(1) (2) (3) (4) (5)
PBC 2 PBC 4 PBC 10 PBC 11 PBC 13
Cancer Endocrine Circulatory Respiratory Gastro-intestinal
2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend
SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14
Outcome Outcome Outcome Outcome Outcome
VARIABLES first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression
LWHITEEG11 -0.389***
[0.060]
lLACARANneed1213 0.743*** 0.870*** 0.847*** 0.817***





















Constant 5.382*** 5.190*** 5.122*** 8.924*** 4.939***
[0.225] [0.252] [0.260] [0.635] [0.138]
Observations 149 149 149 149 149
K-P F statistic 11.26 24.51 19.52 16.64 10.36
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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Table A2.40 First stage of IV regressions, preferred expenditure specifications for 2012/13
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10)
PBC 2 PBC 4 PBC 7 PBC 8 PBC 10 PBC 11 PBC 12 PBC 13 PBC 14 PBC 20
Cancer Endocrine Neurological Vision Circulatory Respiratory Dental Gastro-intestinal Skin Poisoning













































LPOPPUCAR11 -0.404*** -0.292*** -0.467*** -0.451*** -0.467***
[0.128] [0.071] [0.124] [0.117] [0.124]
LLONEPENH11 -0.074 -0.355*** -0.093 -0.075 -0.286*** -0.093
[0.090] [0.063] [0.082] [0.074] [0.064] [0.082]
lLAgall_1213pheadOHP -0.119 0.650*** 0.032 0.693*** 0.055 0.636*** -0.005 0.044 0.499*** 0.693***
[0.230] [0.055] [0.082] [0.073] [0.094] [0.065] [0.093] [0.078] [0.071] [0.073]
lLACARANneed1213 1.259***
[0.289]
LPROFOCCU11 -0.366*** -0.530*** -0.277*** -0.208*** -0.362***
[0.063] [0.074] [0.067] [0.039] [0.042]
LNQUAL17411 -0.072 0.492*** -0.091 0.495*** 0.245*** 0.492***
[0.079] [0.052] [0.070] [0.050] [0.031] [0.052]
LWHITEEG11 0.241*** 0.313*** 0.252*** 0.276***
[0.066] [0.042] [0.041] [0.048]
lLAIMD2010 0.300*** 0.318*** 0.287*** 0.274***
[0.025] [0.041] [0.049] [0.025]
lLAepiprev1213 0.531***
[0.048]








Constant 4.972*** -0.252 6.825*** 0.300 4.068*** 0.738 5.393*** 5.186*** 2.008*** 0.300
[1.674] [0.451] [0.634] [0.546] [0.687] [0.477] [0.574] [0.544] [0.738] [0.546]
Observations 149 149 149 149 149 149 149 149 147 149
K-P F statistic 18.75 43.93 130.4 23.27 65.25 23.54 50.77 122.4 20.12 23.27
Robust standard errors in brackets
*** p<0.01, ** p<0.05, * p<0.1
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